Methods and compositions for HDR template DNA delivery
By using lipid nanoparticles (LNPs) encapsulated with a specific lipid mixture composition to deliver HDR template DNA, the problems of low delivery efficiency and high safety risks in existing technologies have been solved, enabling efficient and safe gene editing in hematopoietic cells.
Patent Information
- Application Number
- CN202580028239.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-17
- Filing Date
- 2025-04-16
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies struggle to efficiently and safely deliver HDR template DNA to hematopoietic cells, especially human primary T cells, and traditional methods such as electroporation and viral transfection present problems such as cell damage, high costs, and safety risks.
Lipid nanoparticles (LNPs) encapsulating HDR template DNA and related gene editing elements in a specific lipid mixture composition are delivered to hematopoietic lineage cells, including T cells, via a non-viral route, improving transfection efficiency and cell survival.
This technology enables efficient and safe delivery of HDR template DNA in human primary T cells, improving knock-in efficiency and cell viability, reducing costs and safety risks, and expanding accessibility to genomic drugs.
Smart Images

Figure CN123125338A_ABST
Abstract
Description
[0001] Cross-references to related applications
[0002] This patent application claims the benefit of U.S. Provisional Patent Application No. 63 / 635,298, filed April 17, 2024, which is incorporated herein by reference in its entirety. Technical Field
[0003] This disclosure generally relates to compositions and methods for delivering homology-directed repair (HDR) template DNA to hematopoietic cells. Background Technology
[0004] Lipid-based nucleic acid (LNP) cell therapy agents offer superior safety and efficacy compared to electroporation in traditional cancer treatment. Transfecting primary human T cells without compromising their survival is extremely challenging, even with lipid nanoparticles as carriers. While mRNA only needs to reside in the cytoplasm, DNA for chromosomal alterations must cross the nuclear membrane to function. Homology-directed repair (HDR) is a mechanism for repairing double-stranded DNA breaks within cells and must occur in the nucleus. HDR approaches for gene therapy using lipid nanoparticles (LNPs) are particularly challenging, especially in primary human cells, which are known to be sensitive to exogenous DNA. Furthermore, the endogenous HDR pathway is inactivated in mature primary cells.
[0005] In many cases, proteins present in the cytoplasm, such as DNases, actively degrade any foreign DNA. However, this degradation process does not apply to mRNA because, in the context of cellular homeostasis, mRNA is not recognized as mislocalized. This difference in cellular response underscores the importance of considering the unique characteristics of mRNA and DNA when developing transfection strategies using LNPs for various cell types, compared to conventional methods such as electroporation.
[0006] Cell therapy involves collecting blood samples from patients or healthy volunteers, isolating or enriching the desired target cells, transforming these target cells, and then reinfusing the cells into donor patients or other patients. One goal of cell therapy is to replace diseased or damaged genetic material with alternative expressed proteins or to enhance innate immunity.
[0007] Currently, electroporation is considered the most feasible non-viral method for gene modification of T cells. This process physically disrupts the cell membrane to force genetic material into the cell, resulting in some T cells undergoing "irreversible electroporation" or death. This process is considered necessary because T cells are resistant to "foreign DNA." There is also a risk of damage to the genetic material before or during transfer. Furthermore, electroporated cells may require a longer period of proliferation, and a recent study showed that T cell viability remained at 37% after electroporation.
[0008] Virus-based T-cell transfection is labor-intensive, costly, and faces challenges in preparation and regulation. Furthermore, virus preparation methods are expensive due to strict regulation, requiring extensive equipment and manpower (and potentially one batch per patient). Virus-based transfection also carries the risk of random viral genome insertion into the human genome and requires patients to be discharged to specialized virus preparation facilities for T-cell collection and processing. Recently, the FDA issued guidance requiring patients receiving cell therapy to be monitored for several years after receiving chimeric antigen receptor (CAR) T or TCR therapy due to the risk of gene integration associated with viral cell manipulation.
[0009] Examples of commercially available cell products for immuno-oncology applications include Kymriah™ for the treatment of B-cell precursor acute lymphoblastic leukemia and Yescarta™ for the treatment of B-cell lymphoma. This ex vivo therapy, also known as CAR-T therapy, involves modified T cells carrying a chimeric antigen receptor targeting CD19 attacking CD19-presenting cancer cells in the patient's body. Leukemia is a leading cause of death in pediatric patients. The use of CAR-T therapy has been transformative in enabling cancer-free recovery for patients.
[0010] Lipid nanoparticles (LNPs) are typically composed of different lipids, each performing a different function. These LNPs can have a lipid core or an aqueous core, and depending on the abundance or structure of the various lipids used, they can contain a bilayer structure. HDR template DNA technology requires not only optimizing the transport of HDR template DNA, but also optimizing the methods for transporting related Cas9 proteins and guide RNA into the cell nucleus. Furthermore, sufficient HDR template DNA must be present at the repair site.
[0011] The recognized challenges in developing successful LNP cell therapies are safety, manufacturability, stability, and efficacy. A superior cell therapy delivery agent that combines high efficiency and high viable cell yield remains needed. Furthermore, there is an urgent need to achieve high-performance HDR (High-Vital-Rate) in human primary T cells using mild, non-viral systems to expand the accessibility of genomic drugs, thereby controlling costs and improving safety. Summary of the Invention
[0012] According to embodiments, the present invention provides compositions and methods for delivering HDR templates to hematopoietic cells with higher efficiency and better cell survival than electroporation or permanent cationic lipids.
[0013] In some embodiments, the LNP is formulated in a lipid composition for cell therapy. In some embodiments, the LNP encapsulates a nucleic acid of interest, such as a gene of interest encoding a protein of interest. In some embodiments, the LNP encapsulates a gene-editing element such as a homologous directed repair (HDR) element or a guide and CRISPR element. In some embodiments, the LNP encapsulates a nuclease. In some embodiments, the LNP encapsulates an HDR element, a guide and CRISPR element, and a nuclease.
[0014] In embodiments, the present invention comprises a composition comprising a first LNP population encapsulating HDR elements and a second LNP population encapsulating gene editing elements, and combinations thereof.
[0015] In an embodiment, for ex vivo applications, the composition is applied to biological samples that have been removed from a organism, which are then processed, washed, and reinfused into the organism. The organism can be a mammal, and can be a human. For example, this method is used for cell reprogramming, gene repair, or immunotherapy. The pharmaceutical product is a modified cell.
[0016] In this embodiment, the present invention provides a method for modifying human T cells with mRNA encoding a chimeric antigen receptor (CAR) to produce CAR-T cell products to be reinfused into a patient, without requiring any viral means to deliver nucleic acids. Non-viral delivery may be a safer technique for modulating the T cells compared to viruses used to reprogram the cells.
[0017] In embodiments, the present invention provides a method for modulating T cell receptors to recognize and destroy neoantigens or tumor antigens present on the surface of tumor cells in a patient, or for modulating T cell populations to treat cancer. In other embodiments, T cells may also be modified to improve autoimmune diseases such as celiac disease, lupus, and diabetes.
[0018] On one hand, the present invention provides lipid nanoparticles (LNPs) for transfecting hematopoietic lineage cells, the lipid nanoparticles (LNPs) comprising a lipid mixture composition containing ionizable lipids, the lipid mixture composition encapsulating HDR template DNA, the HDR template DNA containing a gene of interest for insertion into a target chromosomal locus. In an embodiment, the HDR template DNA is double-stranded.
[0019] In this embodiment, the HDR template DNA is single-stranded.
[0020] In one embodiment, the HDR template DNA contains a chimeric antigen receptor.
[0021] In an embodiment, the LNP further comprises a nuclease or mRNA encapsulated by the lipid mixture composition, wherein the mRNA encapsulates the nuclease.
[0022] In this embodiment, the endonuclease is a CRISPR-associated endonuclease.
[0023] In an embodiment, the LNP further comprises a single guide RNA.
[0024] In an embodiment, the HDR template DNA is accompanied by a guide RNA in combination with a nuclease or an mRNA encoding the nuclease.
[0025] In the embodiments, the lipid mixture composition provides higher knock-in efficiency in primary T cells via LNP-mediated delivery of the HDR template DNA compared to lipid mixture compositions containing MC3 (4-(dimethylamino)butyric acid, (10Z,13Z)-1-(9Z,12Z)-9,12-octadecadien-1-yl-10,13-nonadecanadien-1-yl ester) or SM-102 (8-{(2-hydroxyethyl)[6-oxo-6-(undecoxy)hexyl]amino}octanoic acid 9-heptadecyl ester).
[0026] In an embodiment, the ionizable lipid comprises a tetrahydrofuranyl or cyclopentyl head group.
[0027] In the embodiments, the ionizable lipids comprise PNI 516, PNI 550, PNI 580, PNI 659, PNI 714, PNI 726, PNI 728, PNI 761, PNI 762, PNI 768, PNI 769, PNI 771, or any combination thereof.
[0028] In the embodiments, the lipid mixture composition further comprises structural lipids, sterols, stabilizers, or any combination thereof.
[0029] In an embodiment, the lipid mixture composition comprises about 20-50 mol% ionizable lipids, about 10-70 mol% structured lipids, about 10-70 mol% sterols, and about 0.5-3 mol% stabilizers, wherein the total mol% of the components in the lipid mixture composition is 100 mol.
[0030] In the embodiments, the stabilizer comprises polyoxyethylene (10) stearyl ether (BrijS10), tocopherol polyethylene glycol succinate (TPGS), PEG-DMG, dodecyl maltodextrin, sucrose monolaurate, or any combination thereof.
[0031] In an embodiment, the lipid mixture composition comprises about 20-50 mol% ionizable lipids, about 10-70 mol% structured lipids, about 10-70 mol% sterols, and about 0.5-3 mol% stabilizers, wherein the total mol% of the components in the lipid mixture composition is 100 mol.
[0032] In the embodiments, the lipid mixture composition comprises about 40 Mol% ionizable lipids, about 20 Mol% distearate phosphatidylcholine (DSPC), about 37.5 Mol% cholesterol, and about 2.5 Mol% polyoxyethylene (10) stearyl ether (BrijS10).
[0033] In an example, the lipid mixture composition comprises about 40 Mol% ionizable lipids, about 20 Mol% distearate phosphatidylcholine (DSPC), about 39 Mol% cholesterol, and about 0.75 Mol% tocopherol polyethylene glycol 1000 succinate (TPGS).
[0034] On the other hand, the present invention provides a lipid mixture composition for encapsulating HDR template DNA, the HDR template DNA comprising a gene of interest for insertion into a desired chromosomal locus, the lipid mixture composition comprising ionizable lipids.
[0035] In the embodiments, the lipid mixture composition provides higher knock-in efficiency in primary T cells via LNP-mediated delivery of the HDR template DNA compared to lipid mixture compositions containing MC3 (4-(dimethylamino)butyric acid, (10Z,13Z)-1-(9Z,12Z)-9,12-octadecadien-1-yl-10,13-nonadecanadien-1-yl ester) or SM-102 (8-{(2-hydroxyethyl)[6-oxo-6-(undecoxy)hexyl]amino}octanoic acid 9-heptadecyl ester).
[0036] In an embodiment, the ionizable lipid comprises a tetrahydrofuranyl or cyclopentyl head group.
[0037] In the embodiments, the ionizable lipids comprise PNI 516, PNI 550, PNI 580, PNI 659, PNI 714, PNI 726, PNI 728, PNI 761, PNI 762, PNI 768, PNI 769, PNI 771, or any combination thereof.
[0038] In the embodiments, the lipid mixture composition further comprises structural lipids, sterols, stabilizers, or any combination thereof.
[0039] In the embodiments, the stabilizer comprises polyoxyethylene (10) stearyl ether (BrijS10), tocopherol polyethylene glycol succinate (TPGS), PEG-DMG, dodecyl maltodextrin, sucrose monolaurate, or any combination thereof.
[0040] In an embodiment, the lipid mixture composition comprises about 20-50 mol% ionizable lipids, about 10-70 mol% structured lipids, about 10-70 mol% sterols, and about 0.5-3 mol% stabilizers, wherein the total mol% of the components in the lipid mixture composition is 100 mol.
[0041] In the embodiments, the lipid mixture composition comprises about 40 Mol% ionizable lipids, about 20 Mol% distearate phosphatidylcholine (DSPC), about 37.5 Mol% cholesterol, and about 2.5 Mol% polyoxyethylene (10) stearyl ether (BrijS10).
[0042] In an example, the lipid mixture composition comprises about 40 Mol% ionizable lipids, about 20 Mol% distearate phosphatidylcholine (DSPC), about 39 Mol% cholesterol, and about 0.75 Mol% tocopherol polyethylene glycol 1000 succinate (TPGS).
[0043] On another front, the present invention provides a method for transfecting hematopoietic lineage cells, the method comprising: contacting hematopoietic lineage cells with lipid nanoparticles (LNPs) comprising a lipid mixture composition containing ionizable lipids, the lipid mixture composition encapsulating HDR template DNA containing a gene of interest for insertion into a desired chromosomal locus, thereby transfecting the cells; and culturing the cells in a cell culture medium.
[0044] In an embodiment, the method further includes isolating the cells from the cell culture medium.
[0045] In this embodiment, the HDR template DNA is double-stranded.
[0046] In this embodiment, the HDR template DNA is single-stranded.
[0047] In one embodiment, the HDR template DNA contains a chimeric antigen receptor.
[0048] In an embodiment, the HDR template DNA is accompanied by a nuclease or mRNA encoding the nuclease.
[0049] In this embodiment, the endonuclease is a CRISPR-associated endonuclease.
[0050] In this embodiment, the HDR template DNA is accompanied by a single-guide RNA.
[0051] In one embodiment, the cell is contacted with the LNP containing the HDR template DNA, the HDR template DNA being accompanied by a guide RNA combined with a nuclease or an mRNA encoding the nuclease.
[0052] In one embodiment, the cell is contacted with a plurality of LNPs, each of the plurality of LNPs containing the HDR template DNA, guide RNA and / or endonuclease.
[0053] In an embodiment, the method further comprises contacting the cells with a homology-directed repair enhancer, wherein the homology-directed repair enhancer comprises an HDR enhancer, an NHEJ inhibitor, a DNA sensor inhibitor, or a cell cycle synchronization molecule.
[0054] In the embodiments, the target cell density is between 100,000 cells / mL and 1,000,000 cells / mL.
[0055] In an embodiment, contacting hematopoietic lineage cells involves transfecting primary T cells with the lipid nanoparticles (LNPs), wherein the LNPs, when delivering the HDR template DNA in primary T cells, provide higher knock-in efficiency compared to lipid nanoparticles comprising MC3 (4-(dimethylamino)-butyric acid, (10Z,13Z)-1-(9Z,12Z)-9,12-octadecadien-1-yl-10,13-nonadecanadien-1-yl ester) or SM-102 (8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoic acid 9-heptadecyl ester).
[0056] In an embodiment, the ionizable lipid comprises a tetrahydrofuranyl or cyclopentyl head group.
[0057] In the embodiments, the ionizable lipids comprise PNI 516, PNI 550, PNI 580, PNI 659, PNI 714, PNI 726, PNI 728, PNI 761, PNI 762, PNI 768, PNI 769, PNI 771, or any combination thereof.
[0058] In the embodiments, the lipid mixture composition of the LNP further comprises structural lipids, sterols, stabilizers, or any combination thereof.
[0059] In the embodiments, the stabilizer comprises polyoxyethylene (10) stearyl ether (BrijS10), tocopherol polyethylene glycol succinate (TPGS), PEG-DMG, dodecyl maltodextrin, sucrose monolaurate, or any combination thereof.
[0060] In an embodiment, the lipid mixture composition comprises about 20-50 mol% ionizable lipids, about 10-70 mol% structured lipids, about 10-70 mol% sterols, and about 0.5-3 mol% stabilizers, wherein the total mol% of the components in the lipid mixture composition is 100 mol.
[0061] In the embodiments, the lipid mixture composition comprises about 40 Mol% ionizable lipids, about 20 Mol% distearate phosphatidylcholine (DSPC), about 37.5 Mol% cholesterol, and about 2.5 Mol% polyoxyethylene (10) stearyl ether (BrijS10).
[0062] In an example, the lipid mixture composition comprises about 40 Mol% ionizable lipids, about 20 Mol% distearate phosphatidylcholine (DSPC), about 39 Mol% cholesterol, and about 0.75 Mol% tocopherol polyethylene glycol 1000 succinate (TPGS).
[0063] Further and alternative aspects and features of the disclosed principles will be understood through the following detailed description. It will be understood that the compositions and methods disclosed herein can be implemented and used in other and different embodiments, and can be modified in various aspects. Therefore, it should be understood that the foregoing general description and the following detailed description are merely exemplary and explanatory, and do not limit the scope of the appended claims. Attached Figure Description
[0064] Figure 1A-1B This is a bar chart and cytology diagram showing the effect of cell density on homology-directed repair (HDR) efficiency during lipid nanoparticle (LNP)-mediated gene insertion in primary T cells. Figure 1A The percentage of normalized HA+ / CD5+ live T cells relative to wild-type untreated controls is shown at different cell densities (100,000 cells / mL, 250,000 cells / mL, 500,000 cells / mL and 1,000,000 cells / mL). Figure 1B A representative 2D flow cytometry plot comparing the frequency of HA-labeled CD5+ cells at two contrasting cell densities of 1 million cells / mL and 100,000 cells / mL is shown.
[0065] Figure 2A-2B The dynamics of LNP treatment HDR efficiency are shown when Cas9 mRNA + sgRNA and ssODN delivery are temporally separated in primary T cells. Figure 2A A timeline diagram of the CRISPR component delivery dates is shown for two sets of experiments. In the first set of experiments, which demonstrates simultaneous delivery, all components (Cas9 mRNA, sgRNA, and ssODN) were delivered on day 1 (D1), day 2 (D2), or day 3 (D3). In the second set, Cas9 mRNA and sgRNA were delivered first, followed by staggered delivery of ssODN 24 hours later. Figure 2B Raw HA+CD5+ levels are shown, with background levels indicated as untreated (UT), covering multiple time points (D1, D2, D3) and conditions: simultaneous delivery of all components (Dx All, x = 1, 2, or 3), and staggered delivery with ssODN added 24 hours after Cas9 / sgRNA treatment (Dx Cas9 + 24-hour ssODN). Each treatment was further subdivided by the weight of Cas9 mRNA / sgRNA and ssODN added per million T cells (5 μg: 1 μg, 1 μg: 1 μg, 5 μg: 5 μg, 5 μg: 10 μg). Simultaneous delivery of all components was observed to show significantly improved HDR efficiency compared to staggered delivery with ssODN added 24 hours after Cas9 / sgRNA treatment. In the simultaneous delivery case, the highest HDR efficiency was observed at the maximum tested dose (5 μg Cas9 / sgRNA: 10 μg ssODN per million T cells) among the various tested doses. Error bars represent the standard deviation between technical repetitions.
[0066] Figures 3A-3C A comparison of HDR efficiency between different LNP configurations is shown. Figure 3A A schematic diagram depicting the LNP encapsulation strategy is shown: (i) encapsulating Cas9 mRNA and sgRNA in one LNP, while encapsulating ssODN in a separate LNP (“separate”), or (ii) encapsulating all three components in the same LNP (“integrated”). Figure 3B This is a bar chart showing the HDR efficiency measured by the frequency of HA+ CD5+ primary T cells after treatment with LNPs encapsulating CRISPR / Cas9 components in a “separate” or “integrated” manner. Figure 3C The cell viability of HA+ CD5+ primary T cells was demonstrated after treatment with LNPs encapsulating CRISPR / Cas9 components in either a "single" or "integrated" manner.
[0067] Figures 4A-4F are bar charts and cytological plots illustrating the evaluation of HDR efficiency and cell viability using different concentrations of Alt-R™ HDR enhancer V2 (IDT, Coralville, IA). Figures 4A-4C show LNPs generated on the NanoAssmblr® Spark™ nanoparticle formulation system (Cytiva, Marlborough, MA) without further purification. Figures 4D-4F show LNPs generated on the NanoAssmblr® Ignite™ nanoparticle formulation system (Cytiva, Marlborough, MA) after complete buffer replacement and cleaning. Figure 4A shows the HDR efficiency of LNPs containing Cas9 mRNA, sgRNA, and ssODN generated on the NanoAssmblr® Spark™ at different concentrations of HDR enhancer V2 as indicated. Figure 4B shows the corresponding cell viability normalized relative to the untreated control at the indicated HDR enhancer concentration. Figure 4C shows representative 2D flow cytometry plots illustrating HA+CD5+ T cell frequencies at 0 μM and 4 μM HDR enhancer V2. Figure 4D shows the HDR efficiency of LNPs containing Cas9 mRNA, sgRNA, and ssODN generated on NanoAssemblr Ignite at different concentrations of HDR enhancer V2 as indicated. Figure 4E shows the corresponding cell viability at the indicated HDR enhancer concentrations relative to the untreated control, normalized. Figure 4F shows representative 2D flow cytometry plots illustrating HA+ / CD5+ T cell frequencies at 0 μM and 4 μM HDR enhancer V2. Error bars indicate technique reproducibility.
[0068] Figures 5A-5B The effects of small molecules and nucleic acid modulators on HDR efficiency and cell viability when using PNI 550-LNP_1 LNP are shown. Figure 5A This is a bar chart showing the knock-in efficiency (HA+ / CD5+) after treatment with PNI 550-LNP_1 LNP at different modifier doses (0-20 μM). The modifiers tested included RU521 alone, Alt-RHDR enhancer V2 alone, a combination of RU521 and V2, BX795, XL413, and A151. Figure 5BThe corresponding cell viability, determined by flow cytometry, is shown after treatment with the indicated modulators. The data demonstrate that each modulator possesses different toxicity characteristics, with BX795 maintaining high cell viability at all tested doses, while the Alt-R HDR enhancer V2 significantly reduced cell viability at higher concentrations. The effects of using XL413, A151, and RU521 alone on knock-in and viability were negligible.
[0069] Figures 6A-6B This study demonstrates a comparison of LNP-mediated HDR in primary human T cells between proprietary PNI ionizable lipids and benchmark lipids. Figure 6A The bar chart shows the HA+CD5+ knock-in efficiency relative to the untreated control, comparing PNI 550 formulated in LNP_1 with the baseline lipid composition (SM-102, MC3, BOCHD-DMA) formulated in LNP_1 and SM-102 formulated in Spikevax formulation. Figure 6B The bar chart shows HDR efficiency as a GFP+TCR-cell frequency, demonstrating superior gene insertion of PNI lipids compared to MC3 (Onpattro®) and SM-102 (Spikevax®), with error bars reflecting both technology and donor differences. Experiments were performed at the TRAC locus using a large DNA donor (approximately 2.5 kb, GFP expression).
[0070] Figures 7A-7D are bar charts and cytological plots showing the HDR editing efficiency in primary human T cells using LNPs formulated with different PNI ionizable lipids and compositions. Figure 7A shows an expanded screening of ionizable lipids (PNI-550, 659, 762, 768, and 769) in the LNP_1 formulation. Figure 7B shows a representative flow cytometry 2D plot of PNI 550, PNI 762, and PNI 659 showing the distribution of CD5 and HA antibody-stained cells. Figure 7C is a bar chart showing the HA+CD5+ knock-in efficiency of two LNP formulations (LNP_1 and LNP_2) using ionizable lipids PNI-550, 762, or 516. Figure 7D shows the CAR+TRAC knock-in efficiency, comparing LNP_1 and LNP_2 formulated with ionizable lipids (PNI-550, 762, or 516), reflecting the editing performance using large donor DNA (3.5 kb) at the TRAC locus.
[0071] Figures 8A-8B The HDR efficiency of various LNP formulations in primary T cells with and without Alt-R HDR enhancer V2 is shown. Figure 8AAn evaluation of HDR efficiency using LNP formulated with PNI 550 ionizable lipids is shown, with and without the indicated HDR enhancer. Figure 8B Parallel evaluations of compositions employing PNI 762 ionizable lipids are shown.
[0072] Figures 9A-9B The HDR efficiency and cell viability of different LNP_1-related formulations are evaluated. Figure 9A This is a bar chart showing HDR efficiency as a percentage of HA+ / CD5+ primary T cells (normalized relative to untreated controls) after treatment with various LNP formulations including PNI 550-LNP_1 and PNI 762-LNP_1. Formulation PNI 762-LNP_1 exhibited the highest HDR efficiency among all the compositions tested. Figure 9B The corresponding cell viability (relative to untreated cells) is shown as determined by flow cytometry. All formulations maintained high viability, indicating that changes in the lipid mixture composition did not adversely affect T cell viability.
[0073] Figures 10A-10C The study compares the HDR knock-in efficiency, post-treatment cell viability, and cell yield between electroporation and LNP-mediated delivery of PNI 550-LNP_1 in primary T cells. Figure 10A This is a bar chart showing the HDR efficiency as a function of HA+ / CD5+ frequency in primary T cells. Similar HDR rates were achieved in two replicate experiments using electroporation (EP) and the PNI 550-LNP_1 LNP delivery method in healthy donors. Figure 10B Cell viability after treatment, as assessed by flow cytometry, is shown. The percentage of cell viability shows that PNI 550-LNP_1 LNP delivery (viability of 103% relative to the untreated control) was slightly better than electroporation (viability of 95% relative to the untreated control). Figure 10C The edited cell yield (HA+ cell count per mL) is shown, determined by acridine orange / propidium iodide (AO / PI) staining and automated cell counting. HA+ cell yield generated by PNI 550-LNP_1 LNP delivery (2 × 10⁻⁶ cells per mL). 5 The number of counts was significantly higher than that of electroporation (4 × 10⁻⁶ per mL). 4 (Number of counts). Error bars represent the standard deviation of the measurements, and individual data points from each biological repetition are shown as points on the bar chart. No HDR enhancers or similar agents were included in the experiment.
[0074] Figure 11A-11EThis study presents a comparison of multi-donor HDR editing results using LNP-mediated delivery versus electroporation (EP) delivery in primary T cells. Figure 11A This is a bar chart showing the percentage of CD19CAR+ / TCR- viable cells after HDR editing via PNI 762-LNP_1 or EP. Figure 11B The corresponding post-treatment cell viability (normalized relative to untreated control) was measured by flow cytometry in multiple donors. Figure 11C The figure shows the fold increase in the T cell population relative to the initial cell count up to day 7. Figure 11D The yield of CD19 CAR+ cells is shown, indicating the total cell count after treatment. Figure 11E The cytotoxic activity of LNP_1-edited CAR T cells, measured after co-incubation for 48 hours with CD19+ SUP-B15 target cells or CD19- K562 controls at various effector-target ratios, is shown. In all figures, error bars represent the standard deviation of biological replicates. Detailed Implementation
[0075] According to one embodiment of the present invention, a method for converting T cells using HDR elements is provided without destructive physical methods such as electroporation.
[0076] On the other hand, the present invention provides a lipid mixture composition comprising an ionizable lipid, one or more phospholipids, and a stabilizer.
[0077] On the other hand, a lipid mixture composition according to the invention is provided for formulation of in vitro cell therapy products, wherein the modified cells are pharmaceutical products.
[0078] On the other hand, the present invention provides a lipid mixture composition for formulating mRNA LNPs.
[0079] In an embodiment, the present invention provides a composition for transfecting hematopoietic lineage cells, the composition comprising lipid nanoparticles (LNPs) encapsulating HDR template DNA. In an embodiment, the cells are T cells.
[0080] In embodiments, the LNP comprises an ionizable lipid, a phospholipid, and a stabilizer. In embodiments, the ionizable lipid has a cyclopentyl head group or a tetrahydrofuranyl head group. In embodiments, the LNP comprises an ionizable lipid, including PNI 516, PNI 550, PNI 580, PNI 714, PNI 726, PNI 728, PNI 761, PNI 762, PNI 768, PNI 769, PNI 771, or combinations thereof.
[0081] In one embodiment, the DNA contains a homology-directed repair (HDR) template. In one embodiment, the mRNA contains a gene-editing element. In one embodiment, the gene-editing element includes a Cas9 system element. In one embodiment, the present invention provides a composition comprising a combination of LNP compositions as described herein.
[0082] In embodiments, the present invention provides modified hematopoietic lineage cells comprising hematopoietic lineage cells modified by the methods described herein. In embodiments, the present invention provides a treatment method comprising administering an effective amount of a composition of the modified cells described herein to a subject in need.
[0083] Various further aspects and embodiments of this disclosure are provided in the following description. Before further describing in detail the various embodiments of the currently disclosed inventive concept through exemplary description, examples, and results, it should be understood that the currently disclosed inventive concept is not limited in application to the details of the methods and compositions set forth in the following description. The currently disclosed inventive concept can have other embodiments or can be practiced or carried out in various ways. Therefore, the language used herein is intended to give the broadest possible scope and meaning; and the embodiments are intended to be exemplary and not exhaustive. Likewise, it should be understood that the wording and terminology used herein are for descriptive purposes and should not be considered limiting unless otherwise stated. Furthermore, numerous specific details are set forth in the following detailed description to provide a more thorough understanding of this disclosure. However, it will be apparent to those skilled in the art that the currently disclosed inventive concept can be practiced without these specific details. In other instances, features well known to those skilled in the art have not been described in detail to avoid unnecessarily complicating the description. All compositions disclosed herein, as well as their production, application, and methods of use, can be made and performed according to this disclosure without excessive experimentation.
[0084] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if specifically and individually indicated that each individual publication, patent, or patent application is incorporated by reference. Unless otherwise defined, all technical and scientific terms and any acronyms used herein have the same meaning as commonly understood by one of ordinary skill in the art of this invention. While any methods and materials similar to or equivalent to those described herein may be used in the practice of this invention, exemplary methods, apparatus, and materials are described herein.
[0085] The present invention can be practiced using conventional techniques in molecular biology (including recombinant technology), microbiology, cell biology, biochemistry and immunology within the scope of the art. These techniques are well explained in the following literature and their latest editions: *Molecular Cloning: A Laboratory Manual*, 2nd edition (Sambrook et al., 1989), Cold Spring Harbor Press; *Oligonucleotide Synthesis* (edited by MJ. Gait, 1984); *Methods in Molecular Biology*, Humana Press; *Cell Biology: A Laboratory Notebook* (edited by J.E. Cellis, 1998), Academic Press; *Animal Cell Culture* (edited by RI. Freshney, 1987); *Introduction to Cell and Tissue Culture* (JPMather and PE. Roberts, 1998), Plenum Press; *Cell and Tissue Culture: Laboratory Procedures*. Procedures (edited by A. Doyle, JB. Griffiths, and DG. Newell, 1993–1998), J. Wiley and Sons; Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (edited by D.M. Weir and C.C. Blackwell); Gene Transfer Vectors for Mammalian Cells (edited by JM. Miller and MP. Calos, 1987); Current Protocols in Molecular Biology (F.M.).*Ausubel et al. (eds., 1987)*; *PCR: The Polymerase Chain Reaction* (eds., Mullis et al., 1994)*; *Current Protocols in Immunology* (eds., JE Coligan et al., 1991)*; *Short Protocols in Molecular Biology* (Wiley and Sons, 1999)*; *Immunobiology* (CA. Janeway and P. Travers, 1997)*; and *Cancer: Principles and Practice of Oncology* (eds., VT DeVita et al., JB Lippincott Company, 1993). While any methods and materials similar to or equivalent to those described herein may be used in the practice of this invention, exemplary methods, apparatus, and materials are described herein. For the purposes of this disclosure, the following terms are defined as follows. Other definitions are set forth throughout this disclosure.
[0086] In this disclosure, the use of endpoints to describe a range of numbers includes all numbers contained within that range, including all full numbers, all integers, and all fractional intermediates (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5, etc.). In this disclosure, unless the context clearly indicates otherwise, the singular forms “a / an” and “the” include plural references. Thus, for example, a reference to a composition containing “compound” includes a mixture of two or more compounds.
[0087] In this disclosure, unless the context clearly indicates otherwise, the term "or" is generally used in a meaning that includes "and / or".
[0088] As used herein, the term "about" is defined as plus or minus 12.5% of the listed value. It indicates that the desired target concentration might be, for example, 40 mol%, but the actual percentage may deviate by + / - 5 mol% due to mixing inhomogeneities. As used herein, the term "substantially" is defined as plus or minus 5% of the listed value. It indicates that the desired target concentration might be, for example, 40 mol%, but the actual percentage may deviate by + / - 2 mol% due to mixing inhomogeneities.
[0089] In this disclosure, the term "comprising" is used in a non-limiting sense to mean including the items that follow the word, but does not exclude items not specifically mentioned. It should be understood that in embodiments that include or may include specific features, variables, or parameters, alternative embodiments may consist of, or substantially consist of, such features, variables, or parameters. The use of the indefinite article "a" to refer to an element does not exclude the possibility of more than one of the elements, unless the context explicitly requires one and only one of the elements.
[0090] In this disclosure, "transfection" means the transfer of nucleic acids into cells. In some cases, the aim is to induce the expression of a specific gene of interest in both laboratory and clinical settings. In other cases, the aim is to suppress the expression or function of harmful genes. In still other non-limiting cases, the aim is to perform gene editing. It typically involves ionizable lipids associated with nucleic acids, as well as phospholipids. LIPOFECTIN™ and LIPOFECTAMINE™ are established commercial transfection reagents marketed by Thermo Fisher Scientific. These research reagents contain permanent cationic lipids and are not suitable for in vivo or in vitro use.
[0091] In this disclosure, the terms "modified," "genetically modified," or "transfected" are used interchangeably, referring to cells that have been manipulated through molecular reprogramming of their genome sequence (e.g., by insertion, deletion, or substitution). The cells include primary transformed cells and their derived progeny, regardless of passage number. The nucleic acid content of the progeny may not be exactly the same as that of the parent cells, but may contain mutations. This includes mutant progeny with the same function or biological activity as those screened or selected from the original transformed cells.
[0092] "Lipids" refers to a diverse group of organic compounds that are fatty acid derivatives or sterols, or lipid-like substances such as lipidoids (examples C12-200), and are characterized by being insoluble in water but soluble in a variety of organic solvents.
[0093] "Lipid mixture composition" refers to components that can be used to prepare lipid nanoparticles (LNPs) for encapsulating payloads. Typically, lipid mixture compositions used to prepare lipid nanoparticles for nucleic acid delivery contain cationic or ionizable lipids, and one or more of phospholipids, cholesterol, or stabilizers. Stabilizers may include polyethylene glycol-conjugated lipids. As used in this disclosure, lipid mixture compositions do not contain a payload.
[0094] "Lipid mixture formulation" refers to the type of components, the ratio of components, and / or the ratio of total components to nucleic acid payload (e.g., LNP including payload).
[0095] Lipid mixture compositions that can be used to mix with nucleic acid components comprise ionizable lipids as described, neutral lipids or phospholipids or “structural” lipids that contribute to the outer bilayer or monolayer of LNPs, optionally cholesterol, and optionally stabilizers as described above. For each application, a specific ratio of these four components can be optimized. For vaccines, a molar percentage of 50% ionizable lipids has been successfully used in clinical products. However, targeted gene delivery to cells while maintaining cell viability requires methods different from those used for intramuscular injection and immediate release. In some embodiments shown below, lipid mixture compositions comprise ionizable lipids (iL), cholesterol, structural lipids, and stabilizers. In some embodiments, stabilizers include PEG DMG, TPGS, polyoxyethylene (40) stearate, polyoxyethylene (10) stearyl ether, polyoxyethylene (20) stearyl ether, tridecyl-D-maltodextrin, polysorbate 20, or polysorbate 80. In some embodiments, lipid mixture compositions may optionally comprise triglycerides.
[0096] Non-limiting examples of lipid mixture compositions (which are interchangeably referred to as "lipid compositions" or "lipid nanoparticle compositions" in this disclosure) include those disclosed in PCT Publications 2020210901 and 2024006863, which are incorporated herein by reference in their entirety. "Lipid particle" or "lipid nanoparticle" or "LNP" refers to lipid particles prepared from the lipid mixture compositions described above and explained below. Therapeutic agents such as nucleic acids can be encapsulated in lipid mixture compositions to provide nucleic acid-containing lipid nanoparticles or nucleic acid lipid nanoparticles (NALNPs, or interchangeably referred to as "LNPs" in this disclosure). In some embodiments, lipid nanoparticles are lipid particles with a diameter of less than 300 nanometers (nm). Lipid particles are typically spherical assemblies of lipids, nucleic acids, cholesterol, and stabilizers. The positive and negative charges, ratios, and hydrophilicity and hydrophobicity of the components of the lipid mixture composition determine the physical structure of the lipid particles in terms of component size and orientation. These lipid particles can be structured to form a hydrous interior with one or more bilayers, as in liposomes, or they can have a solid interior, as in solid nucleic acid lipid nanoparticles. Phospholipid monolayers or bilayers can be present in single or multiple forms. In some embodiments, the diameter of the lipid particles is between 1 nm and 1000 nm.
[0097] When referring to cells in vitro or ex vivo, "viability" means the ability to continue growing, dividing, or continuing to grow and divide, consistent with the normal state of the cell type or tissue culture line. Cell viability is affected by harsh conditions or treatments. Cell viability is crucial in ex vivo therapies or parenteral administration.
[0098] The compositions of the present invention comprise ionizable lipids as a component. As used herein, the term "ionizable lipid" refers to a lipid that is cationic or becomes ionizable (protonated) when the pH decreases below the pKa of the ionizable group of the lipid, but is more neutral at higher pH values. At pH values below the pKa, lipids are capable of associating with negatively charged nucleic acids (e.g., oligonucleotides). As used herein, the term "ionizable lipid" includes lipids that are positively charged when the pH decreases from physiological pH, and any of a variety of lipid species that are net positively charged at a given pH. Non-limiting examples of suitable ionizable lipids are found in PCT Publications WO20252589 and WO21000041, which are incorporated herein by reference in their entirety for all purposes. Ionizable lipids may be present in lipid nanoparticle compositions in any suitable amount or concentration. In some embodiments, the ionizable lipids are present at a concentration of about 10 mol% to about 90 mol% or about 20 mol% to about 70 mol%, for example, about 10 mol%, about 15 mol%, about 20 mol%, about 25 mol%, about 30 mol%, about 35 mol%, about 40 mol%, about 45 mol%, about 50 mol%, about 55 mol%, about 60 mol%, about 65 mol%, or about 70 mol%, about 75 mol%, about 80 mol%, about 85 mol%, about 90 mol%, or a concentration within the range defined by any two of the foregoing values. According to other embodiments of the invention, the ionizable lipids are preferably present in the lipid composition at a ratio of about 10 Mol% to about 60 Mol% (“Mol%” means the percentage of a particular component in moles, while the total moles of all components in the lipid composition is 100 mol%). The term “about” in this paragraph indicates a range of ±5 Mol% in increments of 0.1. For example, 28.7 Mol%, 40 Mol%, 47.5 Mol%, and 50 Mol% of ionizable lipids are all within the scope of the claimed embodiments. In some embodiments, the ionizable lipids are present at about 35 Mol% to 50 Mol% of the lipid mixture composition. DODMA or 1,2-dioleoyloxy-3-dimethylaminopropane is an alternative ionizable lipid, as are DLin-MC3-DMA or O-(Z,Z,Z,Z-heptadec-6,9,26,29-tetraen-19-yl)-4-(N,N-dimethylamino) (“MC3”). LNPs can be generated from lipid compositions including the ionizable lipids of the present invention.
[0099] Representative ionizable lipids disclosed herein include, but are not limited to, PNI 516, PNI 550, PNI 580, PNI 659, PNI 714, PNI 726, PNI 728, PNI 761, PNI 762, PNI 768, PNI 769, PNI 771, or any combination thereof, as described herein. The ionizable lipids of this invention include ionizable lipids containing a cyclopentyl or tetrahydrofuranyl head group.
[0100] As used herein, phospholipids are also referred to as “auxiliary lipids,” “structural lipids,” or “neutral lipids,” and in the embodiments, the phospholipids are incorporated into the lipid mixture compositions and lipid particles of the present invention. Structural lipids may be present in the lipid nanoparticle compositions in any suitable amount. In some embodiments, structural lipids are present in the lipid nanoparticle compositions at concentrations of about 1 mol% to about 75 mol% or about 5 mol% to about 60 mol%, for example, about 1 mol%, about 5 mol%, about 10 mol%, about 15 mol%, about 20 mol%, about 25 mol%, about 30 mol%, about 35 mol%, about 40 mol%, about 45 mol%, about 50 mol%, about 55 mol%, about 60 mol%, about 65 mol%, or about 70 mol%, about 75 mol%, or concentrations within the range defined by any two of the foregoing values. The lipid mixture compositions and lipid particles of the present invention comprise one or more phospholipids, said one or more phospholipids comprising about 25 mol% to 60 mol% of the lipid mixture composition. In some embodiments, the one or more phospholipids are present at about 10 Mol% to 70 Mol% of a lipid mixture formulation. In some embodiments, the one or more phospholipids are present at about 10 Mol% to 50 Mol% of a lipid mixture formulation. In some embodiments, the one or more phospholipids are present at about 10 Mol% to 40 Mol% of a lipid mixture formulation. Suitable phospholipids support particle formation during LNP preparation. Phospholipids refer to any of several lipid classes that exist in anionic, uncharged, or neutral zwitterionic forms at physiological pH. Representative phospholipids include, but are not limited to, diacylphosphatidylcholine, diacylphosphatidylethanolamine, and diacylphosphatidylglycerol, and although not strictly "phospholipids" in the technical sense, are intended to include sphingomyelin (SM), dihydrosphingomyelin, cephalin, and cerebrosides.
[0101] Representative phospholipids include, but are not limited to, zwitterionic lipids, such as distearylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylethanolamine (DOPE), palmitoylphosphatidylcholine (POPC), palmitoylphosphatidylethanolamine (POPE), and dioleoylphosphatidylethanolamine 4-(N-maleimidemethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphatidylethanolamine (DMPE), distearylphosphatidylethanolamine (DSPE), 16-O-monomethylPE, 16-O-dimethylPE, 18-1-transPE, 1-stearoyl-2-oleoylphosphatidylethanolamine (SOPE), and 1,2-ditransoleoyl-sn-glycerol-3-phosphate ethanolamine (transDOPE). In a preferred embodiment, the phospholipid is distearylphosphatidylcholine (DSPC). In a preferred embodiment, the phospholipid is DOPE. In a preferred embodiment, the phospholipid is DSPC.
[0102] In another embodiment, phospholipids are any lipids that carry a negative charge at physiological pH. These lipids include, but are not limited to, phosphatidylglycerols such as dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylglycerol (POPG), cardiolipin, phosphatidylinositol, diacylphosphatidylserine, diacylphosphatidic acid, and other anionic modifying groups linked to neutral lipids. Other suitable phospholipids include glycolipids (e.g., monosialotetrahexosylganglioside GM1). "Stabilizer" or "stabilizing agent" is a term used to denote an agent added to an ionizable lipid, phospholipid, and sterol composition according to the invention. In some embodiments, the stabilizer may include a nonionic stabilizer. Non-limiting examples of nonionic stabilizers include, but are not limited to, polyethylene glycol (PEG), DMG-PEG2000 (1,2-dimyristoyl-rac-glycerol-3-methoxy polyethylene glycol-200), polysorbate (Tweens), TPGS (vitamin E polyethylene glycol succinate), Brij™ S20 (polyoxyethylene (20) stearyl ether), Brij™ 35 (polyoxyethylene lauryl ether, polyethylene glycol lauryl ether), Brij™ S10 (polyethylene glycol octadecyl ether, polyoxyethylene (10) stearyl ether), Myrj™ 52 (polyoxyethylene (40) stearate), or any combination thereof. Further non-limiting examples of stabilizers include those disclosed in PCT applications PCT / EP2024 / 075129, PCT / EP2024 / 075124, and PCT / EP2024 / 075128, which are incorporated herein by reference in their entirety.
[0103] In some embodiments, the stabilizer comprises a PEGylated lipid, including but not limited to PEG-DMG2000 (“PEG-DMG”). Other polyethylene glycol-conjugated lipids may also be used. Stabilizers may be used alone or in combination with each other.
[0104] In some embodiments, no stabilizer is present. In other embodiments, the stabilizer comprises about 0.1 mol% to 5 mol% of the lipid mixture composition. In some embodiments, the stabilizer comprises about 0.5 mol% to 2.5 mol% of the mixture composition. In a preferred embodiment, the stabilizer is present at a concentration greater than 1.0 mol%. In some embodiments, the stabilizer is present at a concentration of 5 mol%. In some embodiments, the stabilizer is present at a concentration of 10 mol% to 15 mol%. In some embodiments, the stabilizer is present at a concentration of 2.5 mol% to 10 mol%. In some embodiments, the stabilizer is present in mol% of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10, or has a mol% value within the range defined by any two of the foregoing values. In other embodiments, the stabilizer is present in a concentration greater than 10 mol% of the mixture composition.
[0105] In some embodiments, sterols are included, and lipid blend compositions for specific applications and lipid particles prepared therefrom include, but are not limited to, cholesterol, β-sitosterol, 20-α-hydroxysterol, and / or phytosterols. In some embodiments of the lipid blend compositions of the present invention, sterols are present at about 15 Mol% to 50 Mol% of the lipid blend composition. In some embodiments, sterols are present at about 15 Mol% to 25 Mol% of the lipid blend formulation. In some embodiments, modified sterols or synthetically derived sterols are present. In the case of cell therapy, delivery is targeted at a specific cell type or population, typically in vitro or ex vivo. In the case of vaccines, delivery is limited to the skin or muscle. As used herein, the term “nucleic acid” is intended to include any oligonucleotide or polynucleotide that, when delivered to cells, produces the desired effect. The definition includes diagnostic and research reagents that follow the same physical principles provided by the present invention. Fragments containing up to 50 nucleotides are generally referred to as oligonucleotides, and longer nucleotides are referred to as polynucleotides. In certain embodiments, the oligonucleotides of the present invention are 20-50 nucleotides in length. In embodiments of the invention, the polynucleotide is 996 to 4500 nucleotides in length, as in the case of messenger RNA. In a particular embodiment, the polynucleotide of the invention comprises up to 14,000 nucleotides.
[0106] The term "nucleic acid" refers to ribonucleotides, deoxynucleotides, modified ribonucleotides, modified deoxyribonucleotides, modified phosphate-sugar-backbone oligonucleotides, other nucleotides, nucleotide analogs, and combinations thereof, and may, as appropriate, be single-stranded, double-stranded, or comprise portions of both double-stranded and single-stranded sequences. Messenger RNA (mRNA) may be modified or unmodified, base-modified, and may include different types of capped structures such as Cap1. In some embodiments, nucleic acid refers to self-amplifying RNA ("saRNA"). In some embodiments, nucleic acid refers to ssODNA and mRNA.
[0107] As used herein, the terms “polynucleotide” and “oligonucleotide” are used interchangeably and refer to single-stranded and double-stranded polymers of nucleotide monomers, including 2’-deoxyribonucleotides (DNA) and ribonucleotides (RNA) linked by phosphodiester bonds, such as 3’-5’ and 2’-5’, reverse linkages, such as 3’-3’ and 5’-5’, branched structures, or internucleotide analogues. Polynucleotides have a structure such as H + NH4 + Trialkylammonium, Mg 2+ Na +Related counterions. Polynucleotides can be composed entirely of deoxyribonucleotides (ssODN), entirely of ribonucleotides (RNA), or a chimeric mixture thereof.
[0108] HDR (Homologous Directed Repair) is a gene editing process that repairs double-stranded DNA breaks using template DNA with homologous sequences. The template can be single-stranded or double-stranded. In the case of a single-stranded template, it is called ssODN. It is commonly used to introduce precise changes or specific mutations into the genome, such as gene editing or gene knockout. HDR is primarily used in genome editing applications. It allows for precise modification of specific genes by introducing changes at the DNA level. This is commonly used in technologies like CRISPR-Cas9 and CRISPR-Cas12a gene editing. HDR allows for highly precise changes in the genome because it relies on homologous sequences.
[0109] Guided repair process. HDR allows the donor strand template of DNA to be copied to the double-strand break (DSB) region.
[0110] Transcription activator-like effector nucleases (TALENs) and zinc finger nucleases (ZFNs) are precision gene editing technologies designed to introduce specific double-strand breaks (DSBs) into DNA. TALENs utilize customizable DNA-binding domains from Xanthomonas bacteria for targeted DNA sequence recognition, while ZFNs employ engineered zinc finger motifs, each binding to a different 3-nucleotide sequence. Both are fused with FokI nucleases for DNA cleavage. Their specificity makes them suitable for targeted gene editing when used in conjunction with donor DNA templates, thereby promoting homology-directed repair (HDR) for genomic modifications such as gene correction or mutation introduction.
[0111] As defined in this article, “cell therapy” encompasses a wide range of medical treatments that utilize living cells to achieve therapeutic goals. This definition is broad, including but not limited to: immunotherapies such as chimeric antigen receptor T-cell (CAR-T) therapy, T-cell receptor (TCR) therapy, and tumor-infiltrating lymphocyte (TIL) therapy, which modify and re-infuse immune cells to target neoplastic diseases; hematopoietic cell therapy, involving the transplantation and manipulation of hematopoietic stem cells (HSCs) for the treatment of hematologic disorders including leukemia and lymphoma, and especially the use of autologous or allogeneic stem cells to treat hereditary diseases; natural killer (NK) cell therapy: these therapies utilize NK cells (cytotoxic lymphocytes essential to the innate immune system) to target tumor cells and pathogen-infected cells; and mesenchymal stem cell (MSC) therapy and other therapies: covering MSC treatments applicable to regenerative medicine and autoimmune diseases. The final category also includes therapies using neural stem cells, induced pluripotent stem cells (iPSCs), and other cell types for a variety of therapeutic applications.
[0112] Examples of nucleic acid payloads that can be encapsulated in the lipid mixture compositions of this disclosure include, but are not limited to: antisense oligonucleotides (ASO), ribozymes, microRNAs (miRNAs), messenger RNAs (mRNAs), transfer RNAs (tRNAs), trans-activated CRISPR RNAs (tracrRNAs), guide RNAs, single guide RNAs, self-amplifying RNAs (SAMs or saRNAs), small nuclear RNAs (snRNAs), small interfering RNAs (siRNAs), short hairpin RNAs (shRNAs), circular RNAs (circRNAs), non-coding RNAs (ncRNAs), self-replicating DNA, locked nucleic acids (LNAs), DNA, replicons, pre-condensed DNA, transposons, single genes, vectors, plasmids or pDNAs, aptamers, or combinations thereof. In some embodiments, the nucleic acid is an antigen-encoded mRNA for prophylactic or therapeutic vaccines, a nucleic acid for gene therapy, or a nucleic acid for incorporation into immunogenic cells, wherein the immunogenic cells are T cells, natural killer cells, dendritic cells, macrophages, or tumor-infiltrating leukocytes. In some embodiments, incorporation is performed in vitro, ex vivo, or in vivo. In some embodiments, the nucleic acid payload is mRNA or saRNA. In some embodiments, the therapeutic agent comprises a nucleic acid. In some embodiments, the nucleic acid payload comprises deoxyribonucleic acid, complementary deoxyribonucleic acid, or a complete gene for gene therapy targeting a variety of diseases, such as cancer, infectious diseases, hereditary conditions, and neurodegenerative diseases. As described herein, nucleic acid payloads, including but not limited to nucleic acid therapeutic agents (NATs) or nucleotides of interest, are incorporated into lipid particles during their formation. More than one nucleic acid therapeutic agent may be incorporated in this manner. The nucleic acid payload may be derived from a natural source, or more commonly obtained through synthesis or culture.
[0113] In the embodiments, nucleic acid reagents or payloads are used to silence genes (e.g., using siRNA), express genes (e.g., using mRNA), edit genomes (e.g., using CRISPR / Cas9), and reprogram cells to return to the source organism (e.g., ex vivo cell therapy for reprogramming immune cells for cancer therapy; autologous transfer or allogeneic transfer).
[0114] The nucleic acids present in the lipid particles according to the invention may include any form of nucleic acid currently known or developed thereafter. The nucleic acids used herein may be single-stranded DNA or RNA, or double-stranded DNA or RNA, or DNA-RNA hybrids. Examples of ssODN include homologous arms at the desired locus and the desired insertion. Examples of double-stranded RNA include siRNA and other RNA interference agents. Single-stranded nucleic acids include antisense oligonucleotides, guide RNAs (including CRISPR-Cas9 gRNA), ribozymes, microRNAs, mRNAs, and triple-forming oligonucleotides. In embodiments, more than one nucleic acid may be incorporated into the lipid particles, for example, by co-incorporating mRNA and guide RNA, or by incorporating different types of nucleic acids, or by incorporating them in combination with proteins.
[0115] In some cases, nucleic acids encode genetically engineered receptors, such as recombinant receptors, that bind specifically to ligands, as well as molecules involved in metabolic pathways or their functional portions. Alternatively, molecules involved in metabolic pathways are recombinant molecules, including exogenous entities. Genetically engineered receptors and molecules involved in metabolic pathways can be encoded by one nucleic acid or two or more different nucleic acids. In some instances, the first nucleic acid can encode a genetically engineered receptor that binds specifically to a ligand, and the second nucleic acid can encode a molecule involved in a metabolic pathway.
[0116] The genes of interest (“GOIs”) are nucleic acid molecules that are expected to be integrated and expressed in cells or bioreactors, or that are present on exosomes and expressed. The genes of interest include those encoding insulin, human growth hormone, CFTR, β-globulin, δ-globulin, γ-globulin, BCL11A, KLF1, CCR5, CXCR4, PPP1R12C (AAVS1), HPRT, albumin, factor VIII, factor IX, LRRK2, Htt, SOD1, C9orf72, TARDBP, FUS, RHO, CFTR, SFTPB, TRAC, TRBC, PD1, CTLA-4, HLA A, HLA B, HLA C, HLA-DP, HLA-DQ, HLA-DR, LMP7, TAP1, TAP2, TAPBP, CIITA, DMD, GR, IL2RG, Rag-1, RFX5, FAD2, FAD3, ZP15, KASII, MDH, EPSPS, or fragments thereof.
[0117] The genes of interest may encode bispecific T-cell conjugate (BiTE) molecules; hormones; cytokines (e.g., IL-2, insulin, IFN-γ, IL-7, IL-21, IL-10, IL-12, IL-15, and TNF-α), chemokines (e.g., MIP-1α, MIP-1β, MCP-1, MCP-3, and RANTES), cytotoxins (e.g., perforin, granzyme A, and granzyme B), cytokine receptors (e.g., IL-2 receptor, IL-7 receptor, IL-12 receptor, IL-15 receptor, and IL-21 receptor), or engineered antigen receptors.
[0118] Nucleic acid payloads can include both genes encoding and non-genes of interest. Coding regions are the instructions for building proteins, essential molecules for the structure, function, and regulation of body cells and tissues. Also known as exons, coding regions are segments of DNA that directly encode the amino acid sequence of a protein. These regions are transcribed into messenger RNA (mRNA), which serves as a template for protein synthesis during translation. Mutations in coding regions can alter the amino acid sequence of the resulting protein, potentially affecting its structure or function. Coding regions are highly conserved across species and are crucial for understanding the genetic basis of hereditary diseases and developing therapeutic interventions.
[0119] Non-coding regions, also known as introns and regulatory sequences, are segments of DNA that do not code for proteins. Introns are spliced out during mRNA processing, and only exons are retained in mature mRNA. Regulatory sequences, such as promoters, enhancers, and silencers, play a crucial role in controlling gene expression by influencing transcriptional activity. Non-coding regions are involved in a variety of cellular processes, including gene regulation, chromatin structure, and RNA processing. Mutations in non-coding regions can affect gene expression levels or patterns, leading to phenotypic changes or disease susceptibility. Non-coding regions also contain repetitive DNA regions, such as transposable elements, which may contribute to genomic instability and genetic diversity.
[0120] The non-coding regions of the genome do not directly encode proteins, but they can encode non-coding RNA (ncRNA). Non-coding RNA is RNA molecule transcribed from DNA but not translated into proteins. Instead, it plays various regulatory and structural functions within the cell. Examples of non-coding RNA include: tRNA molecules involved in translating the genetic code from mRNA into amino acid sequences during protein synthesis; rRNA molecules, which are components of ribosomes, the cellular machinery responsible for protein synthesis, and help catalyze the assembly of amino acids into proteins; miRNAs, small RNA molecules that regulate gene expression by binding to specific mRNA molecules and inhibiting their translation or promoting their degradation; and long non-coding RNA (lncRNA), which is RNA molecule longer than 200 nucleotides and does not encode proteins. They play multiple roles in gene regulation, chromatin organization, and other cellular processes. Small nuclear RNA (snRNA) is involved in the processing of precursor mRNA transcripts, including splicing and other RNA modification processes. Small nucleolar RNA (snoRNA) directs the chemical modification of ribosomal RNA and other RNAs, and Piwi-interacting RNA (piRNA) is involved in silencing the activity of transposon elements in the genome, thereby maintaining genome stability.
[0121] The nucleic acid payload disclosed herein may encode an engineered T-cell receptor (TCR), a chimeric antigen receptor (CAR), a Daric receptor or a component thereof, or a chimeric cytokine receptor.
[0122] As used herein, “therapeutic agents” include nucleic acids, or nucleic acid therapeutic agents (“NAT”), proteins, peptides, polypeptides, and small molecules as described herein.
[0123] The term "peptide" in this document encompasses both "oligopeptides" and "proteins" and their tertiary and quaternary structures, which in some embodiments are therapeutic agents. Oligopeptides typically consist of two to twenty amino acids. A polypeptide is a single linear chain of multiple amino acids of any length linked by amide bonds. Proteins are composed of one or more proteins and may include structural proteins, energy catalysts, albumins, hemoglobins, immunoglobulins, and enzymes.
[0124] The size of the lipid particles of this invention can be evaluated using devices such as Malvern™ Zetasizer™ that measure particle size in solution. The average particle size is typically from 15 nm to 1000 nm. A subgroup of lipid particles is “lipid nanoparticles” or LNPs, with an average diameter of about 15 nm to about 300 nm. In some embodiments, the average particle size is greater than 300 nm. In some embodiments, the diameter of the lipid particles is about 300 nm or less, 250 nm or less, 200 nm or less, 150 nm or less, 100 nm or less, or 50 nm or less. In one embodiment, the diameter of the lipid particles is about 50 nm to about 150 nm. Smaller particles typically exhibit longer circulation times in vivo compared to larger particles. Smaller particles have a stronger ability to reach tumor sites than larger nanoparticles. In one embodiment, the diameter of the lipid particles is about 15 nm to about 50 nm.
[0125] Lipid particles according to embodiments of the present invention can be prepared by standard T-tube mixing techniques, turbulent mixing, milling mixing, stirring to promote ordered self-assembly, or passive mixing of all elements and elemental self-assembly into nanoparticles. Various methods for formulating lipid nanoparticles (LNPs) containing gene-based drugs have been developed. For example, suitable methods are disclosed in U.S. Patent Nos. 5,753,613, 6,734,171, and 7,901,708. These methods involve mixing pre-formed lipid particles with a nucleic acid therapeutic agent (NAT) in the presence of ethanol, or mixing lipids dissolved in ethanol with an aqueous medium containing NAT, and producing lipid particles with a NAT encapsulation efficiency of 65-99%. All these methods rely on ionizable lipids to achieve NAT encapsulation and on stabilizers to inhibit aggregation and the formation of large structures. The properties of the resulting lipid particle system, including size and NAT encapsulation efficiency, are sensitive to various lipid mixture composition parameters such as ionic strength, lipid and ethanol concentrations, pH, NAT concentration, and mixing rate.
[0126] Microfluidic two-phase droplet technology has been applied to generate monodisperse polymer particles for drug delivery or to create large vesicles for encapsulating cells, proteins, or other biomolecules. The use of hydrodynamic focusing to generate size-controllable monodisperse liposomes has also been demonstrated.
[0127] Existing formulation procedures struggle to control parameters such as relative lipid and NAT concentrations and mixing rates during mixing, leading to variations in the properties of the resulting NAT within and between formulations. The novel lipid mixture composition disclosed herein is unique in that it exhibits an unexpectedly low ratio of ionizable lipids to phospholipids. Automated micromixing instruments, such as the NanoAssemblr® instrument (Cytiva, USA), enable rapid and controllable preparation of nanomedicines (liposomes, lipid nanoparticles, and polymer nanoparticles). The NanoAssemblr™ instrument achieves controlled molecular self-assembly of nanoparticles via microfluidic mixing cartridges, which allow for millisecond-level mixing of nanoparticle components at nanoliter, microliter, or larger scales, supporting customization or parallelization. Rapid mixing at small scales allows for reproducible control over particle synthesis and quality, which is impossible with larger instruments.
[0128] Preferred methods employ instruments such as microfluidic mixing devices, like the NanoAssemblr™ series (including Spark™, Ignite™, Blaze™, GMP systems, or commercial mixing systems), to achieve near 100% encapsulation of the nucleic acids used in the formation process within the particles in a single step. In a preferred embodiment, lipid particles are prepared by a process in which approximately 75% to approximately 100% of the nucleic acids used in the formation process are encapsulated within the particles.
[0129] U.S. Patent Nos. 9,758,795 and 9,943,846 describe methods using small-volume mixing techniques and novel formulations obtained therefrom. U.S. Patent No. 10,159,652 describes more advanced methods using small-volume mixing techniques and products for formulating different materials. U.S. Patent No. 9,943,846 discloses a microfluidic mixer with different paths and orifices leading to the element to be mixed. PCT Publication No. 2017117647 discloses a microfluidic mixer with disposable sterile paths. U.S. Patent No. 10,076,730 discloses a bifurcated toroidal microfluidic mixing geometry and its application in microfluidic mixing. PCT Publication No. 2018006166 therefore discloses a programmable automated micromixer and a mixing chip. U.S. design patents D771834, D771833, D772427, D803416, D800335, D800336, and D812242 disclose mixing cartridges with microchannels and mixing geometry for use in mixer instruments sold by Stofan Corporation in the United States.
[0130] In embodiments of the present invention, an apparatus for bio-microfluidic mixing is used to prepare lipid particles according to embodiments of the present invention. The apparatus includes a first reagent stream and a second reagent stream, which are fed into a microfluidic mixer and the lipid particles are collected from the outlet or introduced into a sterile environment.
[0131] The first stream includes the therapeutic agent in a first solvent. Suitable first solvents include solvents that dissolve the therapeutic agent and are miscible with a second solvent. Non-limiting examples of suitable first solvents include aqueous buffers. Representative first solvents include citrate and acetate buffers, or optionally other low-pH buffers.
[0132] The second stream comprises a lipid mixture material in a second solvent. Suitable second solvents include solvents that can dissolve ionizable lipids according to embodiments of the invention and are miscible with the first solvent. Non-limiting examples of suitable second solvents include 1,4-dioxane, tetrahydrofuran, acetone, acetonitrile, dimethyl sulfoxide, dimethylformamide, acids, and alcohols. Representative second solvents include 90% aqueous ethanol or anhydrous ethanol.
[0133] In one embodiment of the invention, a suitable device includes one or more microchannels (i.e., channels with a maximum size of less than 2 mm). In one example, the diameter of the microchannel is from about 20 μm to about 300 μm. In another example, the diameter of the microchannel is from about 300 μm to about 1000 μm. In the example, at least one region of the microchannel has a main flow direction and one or more surfaces defining at least one groove or protrusion having an orientation that forms an angle with the main direction (e.g., an interlaced herringbone mixer), as described in U.S. Patent No. 9,943,846, or a bifurcated annular flow as described in U.S. Patent No. 10,076,730. To achieve maximum mixing rate, it is advantageous to avoid excessive fluid resistance before the mixing zone. Therefore, one example of the device has non-microfluidic channels with a size greater than 1000 μm for delivering fluid to a single mixing channel.
[0134] Less complex mixing methods and instruments, such as those disclosed in U.S. Patent Application Publication No. 20040262223, can also be used to produce the lipid particle formulations of the present invention.
[0135] The lipid mixtures of the present invention can be used to deliver therapeutic agents to cells in vitro, ex vivo, or in vivo. In a particular embodiment, the therapeutic agent is a nucleic acid, which is delivered to cells using the nucleic acid-lipid particles of the present invention. The nucleic acid can be siRNA, miRNA, LNA replicons (including vectors carrying antigenic mRNA), self-amplifying RNA, mRNA, guide RNA, long non-coding RNA (lncRNA), short hairpin RNA (shRNA), aptamers, ribozymes, circular RNA, CRISPR / Cas-based editing cassettes, or DNA molecules such as antisense oligonucleotides (ASO), single-stranded oligonucleotides (ssODN), plasmid DNA (pDNA), vectors, single genes, transposons, PCR amplicons, single-stranded or double-stranded linear DNA, circular DNA, coiled DNA, or supercoiled DNA.
[0136] In other embodiments, the therapeutic agent is an oligopeptide, polypeptide, or protein, which is delivered to cells using the peptide-lipid particles of the present invention. In other embodiments, the therapeutic agent is a mixture of nucleic acids and protein components such as Cas9. The methods and lipid mixture formulations can be readily adapted for delivering any suitable therapeutic agent to treat any disease or condition that may benefit from such treatment.
[0137] In some embodiments, the present invention provides methods for introducing nucleic acids into cells (i.e., transfection). Transfection is a commonly used technique in molecular biology for introducing nucleic acid loads (or NATs) from the extracellular space into the intracellular space for the purpose of transcribing, translating, and expressing the delivered nucleic acid therapeutic agent (NAT) to produce a gene product or downregulate the expression of a disease-related gene. Transfection efficiency is generally defined as one of the following: i) the percentage of cells in the treated total population showing positive expression of the delivered gene, as determined by live-cell or fixed-cell imaging (for detecting fluorescent proteins) and flow cytometry; or ii) the intensity or amount of protein expressed by the treated cells, as analyzed by live-cell or fixed-cell imaging or flow cytometry; or iii) protein quantification techniques such as ELISA or Western blotting. These methods can be performed by contacting the lipid particles or lipid mixture formulations of the present invention with cells for a period of time sufficient to achieve intracellular delivery.
[0138] Typical applications include the intracellular delivery of siRNA in vitro and in vivo using known procedures to knock down or silence specific cellular targets. Alternatively, applications include the delivery of DNA or mRNA sequences encoding polypeptides with therapeutic effects. In this way, therapies for hereditary diseases are provided by delivering defective or missing gene products. The methods of the present invention can be practiced in vitro, ex vivo, or in vivo. For example, the lipid blend formulations of the present invention can also be used to deliver nucleic acids into cells in vivo using methods known to those skilled in the art. In another example, the lipid blend formulations of the present invention can be used to deliver nucleic acids into ex vivo patient cell samples and then return them to the patient.
[0139] The following describes the delivery of nucleic acid loads via lipid particles of the present invention. For in vivo administration, the pharmaceutical composition is preferably administered parenterally (e.g., intra-articular, intravenous, intraperitoneal, subcutaneous, intrathecal, intradermal, intratracheal, intraosseous, intramuscular, or intratumoral). In specific embodiments, the pharmaceutical composition is administered intravenously, intramuscularly, intrathecally, or intraperitoneally via bolus injection. Other routes of administration include local (skin, eye, mucous membrane), oral, pulmonary, intranasal, sublingual, rectal, and vaginal administration. For ex vivo application, the pharmaceutical composition is preferably administered to a biological sample that has been removed from a organism, followed by washing and reinfusion of the cells into the organism. The organism may be a mammal, and specifically a human. For example, this method is used for cell reprogramming, gene repair, or immunotherapy. In one embodiment, the present invention provides a method for modulating the expression of a target polynucleotide or polypeptide. These methods typically involve contacting cells with lipid particles of the present invention, which associate with nucleic acids capable of modulating the expression of the target polynucleotide or polypeptide. As used herein, the term "modulation" refers to altering the expression of a target polynucleotide or polypeptide. Regulation can mean increasing or strengthening, or it can mean decreasing or reducing.
[0140] "Hematopoietic lineage cells" include hematopoietic stem cells, progenitor immune cells such as T cells and B cells, macrophages, or natural killer cells. The term is intended to encompass cells of both the innate and adaptive immune systems.
[0141] B cells can be isolated from whole blood by cell sorting or magnetically activated bead cell sorting. Moore DK, Motaung B, du Plessis N, Shabangu AN, Loxton AG; SU-IRG Consortium Isolation of B-cells using Miltenyi MACS bead isolation kits. PLoS One, 20 March 2019; 14(3). Typically, leukocytes can be isolated from whole blood using density separation. Immune cell isolation involves enriching immune cell subsets using antibody-mediated recognition of specific cell surface antigens, followed by sorting or separation using techniques such as flow cytometry, density centrifugation, or magnetic separation.
[0142] T cells, or T lymphocytes, are a subtype of lymphocytes that play a dominant role in cell-mediated immunity. T cells can be distinguished from other white blood cells (e.g., B cells or natural killer cells) by the presence of T cell receptors on their cell surface. The main categories of T cells include helper (CD4+), cytotoxic (CD8+), memory, and regulatory T cells. For T cell cultures, the logarithmic growth phase is, for example, the time during which cells undergo rapid expansion, approximately day 5 or 6 after activation. The logarithmic phase can be observed by a sudden increase in cell count; this rapid expansion can be used as a time point for initiating the preparation of LNPs for T cell treatment. In embodiments of the invention, T cells can be activated in different ways. The following description uses a triple activation method using anti-CD3 / CD28 / CD2 antibodies as an example, but dual activation is equally effective in studies. Dual activation is performed using anti-CD3 / CD28 antibodies. Current clinical protocols employ a dual activation approach.
[0143] In some cases, T cells can be derived from the differentiation of induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs).
[0144] The preparation of T cells transformed by the method of the present invention includes one or more culture steps and / or preparation steps. T cells are typically isolated from biological tissues derived from mammalian subjects, such as peripheral blood or arterial blood. In some embodiments, the subject from whom the cells are isolated has a disease or condition, or requires cell therapy, or will be given cell therapy. In some embodiments, the subject from whom the cells are isolated is a healthy human donor or volunteer.
[0145] In some embodiments, the cells are primary cells, such as primary human cells. Tissue sources include blood, tissue, lymph, or other tissues taken directly from the subject, as well as samples produced by one or more processing steps such as separation, centrifugation, washing, and / or incubation.
[0146] The tissue source of the derived T cells can be blood or blood-derived tissue, or products of apheresis or leukoablation. Exemplary tissue sources include whole blood, peripheral blood mononuclear cells (PBMCs), leukocytes, bone marrow, thymus, tissue biopsy, tumor, lymph nodes, spleen, or other lymphoid tissue. In some embodiments, the cells are obtained from a different species than those ultimately needed by the subject requiring therapy.
[0147] Cell isolation can include more preparative or affinity-based cell isolation. In some cases, cells are washed, centrifuged, and / or incubated in the presence of one or more reagents, for example, to remove or enrich specific components.
[0148] In some cases, cells are obtained from a subject's circulating blood via apheresis or leukoablation. The blood cells may be washed to remove the plasma fraction and then subjected to subsequent processing steps using appropriate buffers or culture media. In some embodiments, the cells are washed with phosphate-buffered saline (PBS). In some aspects, the washing is performed according to the manufacturer's instructions (e.g., Spectrum Krosflo).
[0149] The GE Akta Flux performs the washing step via tangential flow filtration (TFF). In some embodiments, after washing, the cells are resuspended in a variety of biocompatible buffers, such as those without Ca2+. ++ / Mg ++ PBS.
[0150] Unmodified cells refer to cells that have not undergone any structural or genetic changes after being removed from a living organism. Modified cells refer to cells that have been enhanced or altered in some way during or after removal from a living organism.
[0151] Isolating T cells from tissue sources can involve density-based cell isolation methods, including preparing leukocytes from peripheral blood by lysing erythrocytes and centrifuging with Percoll™ or Ficoll™ gradients. Other methods include isolating different cell types based on the expression or presence of one or more specific surface markers in the cells.
[0152] Specific subsets of T cells, such as cells that are positive for or highly express one or more surface markers, such as CD28. + CD62L + CCR7 + CD27 +CD127 + CD4 + CD8 + CD45RA + and / or CD45RO + T cells can be isolated using positive or negative selection techniques. As an example, CD3 / CD28 conjugated magnetic beads (e.g., DYNABEADS® M-450 CD3 / CD28 T cell amplification beads) can be used to conjugate CD3 / CD28 cells. + CD28 + T cells perform positive selection. CD4 + or CD8 + The selection step can be used to separate CD4. + Helper T cells and CD8 + Cytotoxic T cells. Memory T cells are present in CD8. + CD62L of peripheral blood lymphocytes + and CD62L - Of the two subgroups, CD4 can be performed alternatively. + Selection of helper cells. In some cases, primary CD4 cells... + T lymphocytes are CD45RO - CD45RA + CD62L + CD4 + T cells. In other cases, central memory CD4. + The cells are CD62L + and CD45RO + In other cases, the effect of CD4 + The cells are CD62L - And CD45RO.
[0153] Cell populations can also be separated using affinity magnetic separation technology. The cells to be separated are incubated together with magnetically responsive particles or microparticles, such as paramagnetic beads (e.g., Dynabeads™ (Clontech) or MACS™ (Mitentech) beads). The magnetically responsive material is attached to binding couplers that specifically bind to surface markers present on the cells, multiple cells, or cell populations to be separated. T cells are then separated from tissue-derived cells via a positive or negative selection process, depending on preference. Both kits are available, for example, from StemCell Technologies in Vancouver, Canada.
[0154] For therapeutic purposes, a device is used for separation or sorting, which performs one or more of the following: separation, cell preparation, sorting, processing, and incubation required for T cell transformation. In some aspects, the system is used to perform each of these steps in a closed or sterile environment. In one instance, the system is the one described in U.S. Patent Publication No. 20110003380 A1. Separation and / or other steps can be performed using the CliniMACS system (Miltenyi Biotec). See, for example, Klebanoff et al. (2012) *Journal of Immunotherapy* 35(9): 651-660, Terakura et al. (2012) *Blood* 1:72-82, and Wang et al. (2012) *Journal of Immunotherapy* 35(9):689-701. Desired cell populations can be collected and enriched by flow cytometry, in which cells stained with multiple cell surface markers are carried in a fluid stream. Other methods include FACS or microelectromechanical systems (MEMS) chips combined with FACS-based detection systems (see, for example, WO 2010 / 033140).
[0155] T cell incubation and processing can be performed in culture containers such as chambers, wells, columns, tubes, tube assemblies, valves, vials, culture dishes, bags, jars, or other containers used for culturing or cultivating cells. Stimulating conditions or reagents include one or more agents, such as ligands, capable of activating the intracellular signaling domains of the TCR complex. Incubation can be performed as described in U.S. Patent No. 6,040,177 to Riddell et al. T cell cultures can be expanded by adding non-dividing peripheral blood mononuclear cells (PBMCs) (e.g., such that the resulting cell population contains at least about 5, 10, 20, or 40 or more PBMC feeder cells for each T lymphocyte in the initial population to be expanded); and the culture can be incubated.
[0156] T cell stimulation conditions include a temperature suitable for the growth of human T lymphocytes, such as 25 to 37 degrees Celsius. Optionally, incubation may further include a supportive population of non-dividing EBV-transformed lymphoblasts (LCLs) as feeder cells, at a ratio of 10:1 to naïve T cells.
[0157] In other embodiments, the present invention provides a method for treating a subject with a disease or condition characterized by peptide overexpression, the method comprising providing the subject with a pharmaceutical composition of the present invention, wherein the therapeutic agent is selected from ssODN accompanied by a nuclease and a gene-editing protein and a guide RNA. In still other embodiments, the present invention provides a method for treating a subject with a disease or condition characterized by peptide underexpression, the method comprising providing the subject with a pharmaceutical composition of the present invention, wherein the therapeutic agent is selected from plasmids or DNA comprising a nucleic acid therapeutic agent or a complement thereof that specifically encodes or expresses the underexpressed peptide. In some embodiments, the therapeutic agent is selected from mRNA, self-amplifying RNA (saRNA), or ssODNA, comprising a nucleic acid therapeutic agent or a complement thereof that specifically encodes or expresses the underexpressed peptide. Examples include RNA vaccines, and more specifically self-amplifying mRNA vaccines.
[0158] To deliver a bioactive agent (e.g., RNA encoding an immunogen) to immune system cells (e.g., antigen-presenting cells, including professional antigen-presenting cells), in one embodiment, the formulation of the present invention is delivered intramuscularly, whereby immune cells can infiltrate the delivery site and process the delivered RNA and / or process encoded antigens produced by non-immune cells such as muscle cells. Such immune cells may include macrophages (e.g., bone marrow-derived macrophages), dendritic cells (e.g., bone marrow-derived plasmacytoid dendritic cells and / or bone marrow-derived myeloid dendritic cells), T cells, and monocytes (e.g., human peripheral blood mononuclear cells), etc. (e.g., see WO2012 / 006372).
[0159] DNA is delivered together with the lipid formulations of the present invention (e.g., formulated into liposomes or LNPs). In some embodiments, the present invention utilizes LNPs encapsulated with ssODN encoding an immunogen. Encapsulation within the LNP protects the ssODN from DNase degradation. Encapsulation efficiency need not be 100%. The presence of external bp ssODN molecules (e.g., located on the outer surface of the liposome or LNP) or “naked” DNA molecules (DNA molecules not associated with the liposome or LNP) is acceptable. Preferably, for formulations comprising lipids and DNA molecules, at least half of the DNA molecules (e.g., at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least about 96%, at least about 97%, at least about 98%, or at least 99% of the ssODN molecules) are encapsulated in or complexed with the LNP.
[0160] Some lipid nanoparticles may contain a lipid core (e.g., a formulation may contain a mixture of LNPs and nanoparticles with a lipid core). In this case, DNA or ssODN molecules can be encapsulated in LNPs having one or more aqueous cores and complexed with LNPs having a lipid core through non-covalent interactions (e.g., ionic interactions between negatively charged DNA and cationic lipids). Encapsulation and complexation with LNPs (whether with a lipid core or an aqueous core) can protect DNA from DNase degradation. The encapsulation / complexation efficiency need not be 100%. The presence of “naked” ssODN molecules (DNA molecules not associated with LNPs) is acceptable. Preferably, for formulations containing a population of LNPs and a population of DNA molecules, at least half of the population of DNA molecules (e.g., at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the DNA molecules) are encapsulated in or complexed with LNPs.
[0161] Some lipid nanoparticles have multilayer components, such as phospholipid bilayers and aqueous pockets.
[0162] For the delivery of HDR template DNA or ssODN encoding an immunogen, the preferred range for LNP diameter is 60-180 nm, and in more specific embodiments, 80-160 nm. The LNP may be part of a composition comprising a population of LNPs, and the LNPs in said population may have a range of diameters. For compositions comprising populations of LNPs with different diameters, it is preferred that: (i) at least 80% of the LNPs, by quantity, have a diameter in the range of 60-180 nm, for example, in the range of 80-160 nm; (ii) the average diameter of the population (by intensity, e.g., Z-average) is ideally in the range of 60-180 nm, for example, in the range of 80-160 nm; and / or the polydispersity index of the diameters within the plurality of diameters is < 0.2. To obtain LNPs with the desired diameter, a mixing process can be used where two aqueous DNA solution feed streams are combined with one ethanol lipid solution stream at the same flow rate in a single mixing region, for example, in a microfluidic channel. See other descriptions of the NanoAssemblr® microfluidic mixer sold by Topfan Corporation of the United States.
[0163] In some embodiments, a specific HDR template is used to encode a neoantigen with desired molecular changes in a cancer cell or solid tumor.In some embodiments, the RNA is an mRNA targeting a tumor antigen selected from the following: (a) cancer-testis antigens, such as NY-ESO-I, SSX2, SCPI, and RAGE, BAGE, GAGE, and MAGE family peptides, such as GAGE-1, GAGE-2, MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, and MAGE-12 (which can be used, for example, to treat melanoma, lung cancer, head and neck cancer, NSCLC, breast cancer, gastrointestinal tumors, and bladder tumors); (b) mutant antigens, such as p53 (associated with various solid tumors, e.g., colorectal cancer, lung cancer, head and neck cancer), p21 / Ras (associated with, for example, melanoma, pancreatic cancer, and colorectal cancer), CDK4 (associated with, for example, melanoma), MUMI (associated with, for example, melanoma), cysteine-8 (associated with, for example, head and neck cancer), CIA 0205 (associated with, for example, bladder cancer), HLA-A2-R1701, β-catenin (associated with, for example, melanoma), TCR (associated with, for example, T-cell non-Hodgkin's lymphoma), BCR-abl (associated with, for example, chronic myeloid leukemia), triose phosphate isomerase, KIA 0205, CDC-27, and LDLRFUT; (c) overexpression of antigens, such as galactolectin 4 (associated with, for example, colorectal cancer), galactolectin 9 (associated with, for example, Hodgkin's disease), protease 3 (associated with, for example, chronic myeloid leukemia), WTI (associated with, for example, various types of leukemia), carbonic anhydrase (associated with, for example, renal cell carcinoma), aldolase A (associated with, for example, lung cancer), PRAME (associated with, for example, melanoma), HER-2 / neu (associated with, for example, breast cancer, colon cancer, lung cancer). (d) Shared antigens, such as melanoma-melanocyte antigen, such as MART-1 / Melan A) gp100, MCIR, melanocyte-stimulating hormone receptor, tyrosinase, tyrosinase-associated protein-I / TRPI and tyrosinase-associated protein-2 / TRP-2 (associated with, for example, melanoma); (e) prostate-associated antigens, such as PAP, PSA, PSMA, PSH-PI, PSM-PI, PSM-P2, associating with, for example, prostate cancer; (f) immunoglobulin idiotypes (associated with, for example, myeloma and B-cell lymphoma).In some embodiments, tumor immunogens include, but are not limited to: p15, Hom / Mel-40, H-Ras, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, Epstein Barr virus antigen, EBNA, human papillomavirus (HPV) antigen (including E6 and E7), hepatitis B and C virus antigens, human T-cell lymphoma virus antigen, TSP-180, p185erbB2, p180erbB-3, c-met, mn-23HI, TAG-72-4, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, p16, TAGE, PSCA, CT7, 43-9F, 5T4, 791 Tgp72, β-HCG, BCA225, BTAA, CA 125, CA 15-3 (CA 27.29 and BCAA), CA 195, CA 242, CA-50, CAM43, CD68 and KPI, CO-029, FGF-5, Ga733 (EpCAM), HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB / 70K, NY-CO-I, RCASI, SDCCAG16, TA-90 (Mac-2 binding protein / cyclophilic C-related protein), TAAL6, TAG72, TLP, TPS, etc.
[0164] The compositions according to this disclosure comprise an effective amount of the lipid formulation described herein (e.g., LNP), and any other components as desired. In the examples, the pharmaceutical compositions described herein can be prepared by any method known in the field of pharmacology or developed thereafter. Typically, such preparation methods involve the step of associating the active ingredient with an excipient and / or one or more other auxiliary components.
[0165] The pharmaceutical compositions according to this disclosure can be prepared, packaged, and / or marketed as a single unit dose and / or in multiple single unit doses. As used herein, a “unit dose” means a pharmaceutical composition comprising a discrete amount of a predetermined amount of the active ingredient. The amount of the active ingredient may generally be equal to the dose of the active ingredient to be administered to a subject and / or an appropriate fraction of such dose, including but not limited to one-half or one-third of such dose.
[0166] The relative amounts of the active ingredient, pharmaceutically acceptable excipients, and / or any other components in the pharmaceutical composition according to this disclosure may vary depending on the identity, size, and / or condition of the subject being treated and, more importantly, on the route of administration of the composition. For example, the composition may contain between 0.1% and 99% (w / w) of the active ingredient.
[0167] Pharmaceutical formulations may additionally contain pharmaceutically acceptable excipients, as used herein, including but not limited to any and all solvents, dispersion media, diluents or other liquid media, dispersants or suspending agents, surfactants, isotonic agents, thickeners or emulsifiers, preservatives, etc., suitable for the desired particular dosage form. Various excipients used to formulate pharmaceutical compositions and techniques used to prepare compositions are known in the art (see *Remington: The Science and Practice of Pharmacy*, 21st edition, ARGennaro, Lippincott, Williams and Wilkins, Baltimore, MD, 2006). In addition to the possibility that any conventional excipient media may be incompatible with the substance or its derivatives, the use of conventional excipient media is considered herein, such as by producing any undesirable biological effects or interacting with any other components of the pharmaceutical composition in a harmful manner.
[0168] In some embodiments, the size of lipid particles can be increased and / or decreased. Variations in particle size can help counteract biological responses such as, but not limited to, inflammation, or enhance the biological effects of NATs delivered to mammals by altering their biodistribution. Size can also be used to identify target tissues, where larger particles are rapidly cleared, while smaller particles reach different organ systems. The following describes representative lipid particles (LNPs) prepared with nucleic acids, their preparation methods, evidence of their advantages, and methods for using them to deliver therapeutic benefits.
[0169] Example
[0170] General considerations: Unless otherwise stated, all solvents and reagents are commercial products and should be used accordingly. Temperatures are given in degrees Celsius.
[0171] Abbreviations
[0172] ng = nanogram
[0173] g = grams
[0174] h = hours
[0175] MFI = Median Fluorescence Intensity
[0176] min = minutes
[0177] mL = milliliters
[0178] mmol = millimole
[0179] N / P ratio = The ratio of positively charged lipid amine (N = nitrogen) groups to negatively charged nucleic acid phosphate (P) groups.
[0180] PBS = Phosphate Buffer Solution
[0181] C21-200 = 1,1'-[[2-[4-[2-[[2-[bis(2-hydroxydodecyl)amino]ethyl](2-hydroxydodecyl)amino]ethyl]-1-piperazinyl]ethyl]imino]bis-2-dodecanool
[0182] MC3 = 4-(dimethylamino)butyric acid, (10Z,13Z)-1-(9Z,12Z)-9,12-octadecadien-1-yl-10,13-nonadecanadien-1-yl ester
[0183] SM-102 = 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoic acid 9-heptadecyl ester
[0184] A “gene of interest” (GOI) is one or more genetic elements intended to be expressed to achieve therapeutic goals, including immunity. Chimeric antigens, cancer-associated antigens, autoimmune-associated antigens, and epidermal growth factor (EPO) are examples of GOIs, but GOIs are not limited to these examples.
[0185] iL = Ionizable lipid, a type of lipid that is cationic at lower pH and converts to an uncharged lipid at higher pH. ILs are commonly used in formulations of nucleic acid loads.
[0186] UT = Unprocessed
[0187] The components of a lipid mixture include ionizable lipids, phospholipids, cholesterol, and stabilizers. Low-pH buffers (3-6) can be used. For ionizable lipids, the pH of the buffer is typically lower than the pKa of the lipid.
[0188] Table 1. Examples of ionizable lipids (iL)
[0189]
[0190] The ionizable lipids disclosed herein have an asymmetric center. It should be understood that while specific configurations of non-limiting examples of ionizable lipids are shown in Table 2, in some embodiments, the ionizable lipids may exist as racemates, racemic mixtures, single enantiomers, enantiomer mixtures, single diastereomers or diastereomer mixtures, and all possible isomers and mixtures thereof, such as tautomers.
[0191] Methods and Materials
[0192] Example 1
[0193] T cell isolation
[0194] T cells are isolated from whole blood, erythrocyte sedimentation rate (ESR) amber layer, apheresis products, or other sources obtained from healthy or patient donors. Blood or apheresis materials are treated with anticoagulants such as ACDA, EDTA, or heparin. Purification is performed using immunomagnetic selection methods (e.g., positive selection for CD3 or CD4 / CD8 cells, or negative selection for non-T cell populations) so that the resulting fraction typically contains both CD4+ and CD8+ T cells.
[0195] T-cell cryopreservation and thawing
[0196] Isolated T cells were cryopreserved in a cryoprotectant solution (e.g., 10% DMSO or a proprietary commercial formulation, such as CryoStor® CS10 medium from Stem Cell Technologies) and stored in liquid or gaseous nitrogen. On the day of use, the cryovials were thawed at approximately 37°C. The thawed cells were transferred to basal medium and washed at least once (by centrifugation) to remove residual cryoprotectant. Viable cell counts were obtained using an automated fluorescence cell counter with acridine orange / propidium iodide solution.
[0197] Primary T cell preparation
[0198] T cells must be activated to proliferate and differentiate into effector cells. In the laboratory, activation can be mimicked using a specific set of cytokines (signaling proteins) such as IL-2, as well as other proteins like CD2, CD3, and CD28. After activation, T cells grow rapidly. T cells are activated immediately after thawing or within 24 hours using magnetically bead-bound, plate-bound, or soluble activators that bind to CD3 / CD28, with optional addition of additional co-stimulatory molecules (such as CD2). Depending on scale, activation is performed in flasks, multiwell plates, G-Rex containers (Wilson Wolf Manufacturing, USA), or the Xuri W25 cell expansion system (Stenvent, USA). Cytokines such as IL-2, IL-7, and / or IL-15 are added to support proliferation. Cell density is maintained between approximately 0.1 × 10^6 cells / mL and 2 × 10^6 cells / mL, and the culture is...
[0199] Incubate at 37°C and 5% CO2. Change or perfuse the culture medium as needed to maintain growth and viability.
[0200] T cell expansion
[0201] Following the initial activation phase (typically 1-5 days), T cells can be further expanded in flasks, G-Rex containers, or Xuri cell expansion systems to accommodate large-scale production. Cell density is monitored regularly, and passage culture or culture medium / perfusion is performed to maintain the desired cell density.
[0202] T cell gene modification
[0203] A. LNP-based delivery
[0204] During the 0-4 day period following activation, T cells are treated with an LNP formulation containing mRNA encoding the protein of interest and / or gene-editing components (such as a CRISPR system). A typical dose is approximately 1-10 μg of total nucleic acid per 1 × 10^6 cells, but higher or lower doses may be used depending on the target and experimental design. T cells are incubated for 24-48 hours for transient protein expression or 72-96 hours for gene editing / insertion techniques, during which time the culture medium is changed or perfused as needed.
[0205] B. Electroporation or nuclear transfection
[0206] In contrast, in some instances, T cells were electroporated or transfected using a loading equivalent to LNP (i.e., Lonza's 4D-Nucleofector®). Commercial electroporation protocols were employed (such as EH-140 or EO-100 using recommended buffers), and the transfected T cells were immediately returned to appropriate T cell culture medium for recovery time.
[0207] T-cell analysis and downstream processing
[0208] Genetically modified T cells were collected from day 1 to day 10 (after modification) or later for analysis by flow cytometry and / or functional assays (e.g., cytotoxicity, cytokine secretion). Cells were further expanded, harvested, and / or re-frozen if necessary.
[0209] LNP preparation
[0210] Lipid nanoparticles (LNPs) can be prepared on NanoAssemblr® Spark™, Ignite™, Blaze™, GMP, or commercial formulation systems (Stenvent, USA) for testing. In a non-limiting example, genetic material comprising messenger RNA (mRNA), single / synthetic guide RNA (sgRNA), DNA, or combinations thereof is diluted in an aqueous phase (e.g., 100 mM sodium acetate buffer (pH 4)) to a predetermined concentration (e.g., 0.1 mg / mL to 0.5 mg / mL), depending on the amount of ionizable lipids, the concentration of the lipid mixture, and the desired N / P ratio. The N / P ratio typically ranges from 2 to 20. A non-limiting example of an effective RNA-to-DNA ratio is illustrated in Example 2.
[0211] An organic phase comprising a lipid mixture composition dissolved in an organic solvent was also used. In some cases, concentrations of 12.5 mM, 25 mM, 37.5 mM, or 50 mM were used. However, other concentrations of the lipid mixture composition solution may also be used. In some cases, ethanol was used as the organic solvent, but other organic solvents may be used instead of ethanol. The two fluids, comprising the aqueous phase containing the RNA / DNA payload and the organic phase comprising the lipid mixture composition, were then run in a microfluidic mixer at a predetermined flow rate ratio (e.g., 2:1, 3:1, or 5:1 (aqueous phase:organic phase)) and a predetermined total flow rate (e.g., 8–20 mL / min) to prepare the LNP. Other flow rate ratios and / or flow rates may also be used.
[0212] In some cases, after mixing in a microfluidic device, the cartridge-bound lipid nanoparticle sample, including the payload, is diluted into an RNase-free tube containing approximately 10 to 40 times its volume of pH 7.4 PBS. Ethanol is removed by one of the following methods: dialyzing in phosphate-buffered saline (PBS) at pH 7.4, centrifugation at 2500–4000 RCF using an Amicon™ centrifuge filter (Millipore, USA), or using a TFF system. Once the desired concentration is reached, the lipid nanoparticles are sterilized by aseptic filtration using a 0.2 μm filter.
[0213] Final encapsulation efficiency was measured using the Ribogreen™ assay and the Quant-iT™ RiboGreen® RNA reagent and kit (Invitrogen, USA), as per the manufacturer’s instructions.
[0214] For mRNA, among the observed particle properties, the particle size generally ranged from 50 to 200 nm, depending on the lipid composition and gene therapy payload.
[0215] Guide RNA and DNA template sequence
[0216] Various homology-directed repair (HDR) templates (in the form of single-stranded oligodeoxynucleotides, ssODN, plasmid DNA, double-stranded linear DNA, or single-stranded linear DNA) are encapsulated as part of an LNP, either alone or co-encapsulated with Cas9 mRNA and single-guide RNA (sgRNA). The encapsulation method is shown in Example 3.
[0217] LNP-mediated HDR optimization in primary T cells utilizes CD5 hemagglutinin (HA) labeling, based on the following publication: Shy et al. 2023: Shy, Brian R. et al. “High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails”. Nature Biotechnology 41.4 (2023): 521-531.
[0218] Table 2: CD5 sgRNA and HA tag donors
[0219]
[0220] Other constructs include the use of CD19 chimeric antigen receptor (CAR) plasmid DNA at the TRAC (T cell receptor) locus. The CD19 insert sequence follows the design previously published by Kath et al. (2022), with homologous arms modified to accommodate different sgRNAs: Kath, J., Du, W., Pruene, A., Braun, T., Thommandru, B., Turk, R., and Wagner, DL (2022). Pharmacological interventions enhance virus-free generation of TRAC-replacedCAR T cells. *Molecular Therapy-Methods & Clinical Development*, 25, 311-330.
[0221] Table 3. TCR sgRNA and CD19 CAR and GFP donors (both donors target the same target site)
[0222]
[0223]
[0224]
[0225]
[0226] NHEJ inhibitors, HDR enhancers, and DNA sensor inhibitors
[0227] Small molecules or nucleic acid-based HDR modulators (a non-limiting list in Table 4) can be added directly to T cell cultures or co-encapsulated in lipid nanoparticles for delivery. Depending on the properties of the small molecule, co-encapsulation can be achieved by including it in an aqueous or organic phase during LNP generation. For small molecules such as V2 HDR enhancer, 1–20 μM of the HDR enhancer is added to a cell mixture containing 1 μg / mL ApoE at or up to 12 hours prior to LNP treatment.
[0228] Table 4. Examples of small molecule or nucleic acid-based HDR enhancers.
[0229]
[0230] Tests performed on day 7 after thawing for gene editing:
[0231] AO / PI counting was performed on each well using an automated fluorescence cell counter.
[0232] Table 5. Coloring Matrix
[0233]
[0234] Centrifuge the plate at 300 xg for 5 minutes at room temperature (RT), then discard the supernatant. Add 200 μL of viable dye, specifically FVS660 diluted 1:1000 in PBS (BD Bioscience, 564405), to the treated, untreated, and various fluorescence minus one (FMO) wells. For all other wells, add 200 μL of PBS. Incubate the plate in the dark at room temperature for 10 minutes, then centrifuge again at 300 xg for 5 minutes and discard the supernatant. Subsequently, administer 200 μL of BSA staining buffer (BD Bioscience, 554657) to each well.
[0235] The plate was washed twice, each time involving centrifugation at 300 xg for 5 minutes at room temperature and discarding the supernatant. Antibody staining was then performed for CD5, HA, TCR, or CAR markers. For CD5 and HA staining, the corresponding antibodies were added to the treated, untreated, and viable FMO wells, while BSA staining buffer was added to the unstained and FMO controls. Similarly, TCR and CAR primary antibodies were added to the relevant wells, followed by incubation, addition of BSA staining buffer, washing, and CAR secondary antibody staining.
[0236] After a final 15-minute incubation in the dark at room temperature, wash each well with 200 μL of BSA staining buffer and centrifuge. Resuspend the cell pellet in 0.2% BSA staining buffer or RPMI + 2% FBS, the volume depending on the cell count per well. Cap the plate, protect it from light, and place it on ice until harvesting. The final resuspending volume is optimized for the CytoFLEX™ flow cytometer (Beckman Coulter), but alternative volumes are recommended when using other flow cytometers.
[0237] Tumor cell killing assay
[0238] To assess the antigen-specific cytotoxic activity of engineered T cells, co-culture assays were performed using labeled target cells (SUP-B15, CD19+ or K562, CD19-) and effector anti-CD19 CAR T cells. After thawing, target cells were cultured for at least 7 days in RPMI 1640 medium (R+FBS) supplemented with 10% (v / v) fetal bovine serum, 1 mM sodium pyruvate, 1× MEM, and 1× GlutaMax, and passaged up to 12 times. Prior to co-culture, target cells were pre-labeled with the metabolic activity dye Purple Proliferation Dye 450 (VPD450) to enable downstream identification and cell viability quantification by flow cytometry. Total cell viability was assessed using a second viability staining agent (FVS660) at assay time after co-culturing with effector cells at different effector-to-target ratios (E:T) for 24 or 48 hours. Cytotoxicity was quantified based on the loss of viable target cells. Specific lysis values were calculated compared to untreated target cell controls to determine the relative cytotoxic potency of engineered CAR T cells. Comparison between CD19+ and CD19- target cells allowed for the identification of crowding effects or nonspecific, non-CD19-mediated killing.
[0239] Example 1
[0240] Primary T cells were cultured at densities of 250,000, 500,000, or 1,000,000 cells per milliliter before or during LNP addition. HA+ T cells were quantified 96 hours after transfection with LNP containing Cas9 mRNA, sgRNA, and an HDR template. Significant HDR rates were achieved at all tested densities, ranging from 15% to 28% relative to untreated controls.
[0241] Figure 1A-1B Cell density for LNP-mediated HDR editing in primary T cells is shown. Figure 1A The percentage of normalized HA+ / CD5+ viable T cells relative to wild-type untreated controls is shown at the indicated cell densities (100,000, 250,000, 500,000, and 1,000,000 cells / mL). Significant HDR efficiency was achieved at all test densities from 15% to 28%. Error bars represent three technical replicates. Figure 1B A representative 2D flow cytometry plot comparing the frequency of HA-labeled CD5+ cells at two contrasting cell densities of 100,000 cells / mL and 1,000,000 cells / mL is shown.
[0242] Example 2
[0243] The processing kinetics of LNP-mediated HDR in primary T cells were investigated. ssODN and Cas9 mRNA + sgRNA were delivered simultaneously or staggered. HDR efficiency was assessed by the percentage of HA+ and CD5+ cells. Figure 2A and 2B As shown, the optimal LNP treatment point was observed when all payloads were delivered simultaneously on all test days 1, 2, and 3 (DX all), while efficiency significantly decreased when ssODN-LNP was added 24 hours after Cas9 mRNA / sgRNA delivery (e.g., "all D3" vs. "D3 Cas9 / sgRNA + 24h ssODN"). Figure 2B In addition, in Figure 2B In the samples tested, the condition of 5 μg Cas9 mRNA + sgRNA: 10 μg ssODN provided the highest KI % for HDR efficiency. These results indicate that LNP-mediated delivery of HDR components has a flexible time window. Regarding specific treatment doses, the inferred elevated dose (e.g., compared with...) Figure 2B Compared to other test samples shown, 15 μg total nucleic acid / million cells and excess DNA are beneficial for homologous targeted repair in cells.
[0244] Figure 2A-2BThe LNP treatment kinetics for HDR efficiency in primary T cells are shown when Cas9 mRNA + sgRNA and DNA (e.g., ssODN) delivery is temporally separated. Figure 2A This is a schematic diagram of the experimental timeline for CRISPR component delivery. All components (Cas9 mRNA, sgRNA, and ssODN) were delivered on day 1 (D1), day 2 (D2), or day 3 (D3). An additional group included those that delivered Cas9 mRNA and sgRNA first, followed by staggered delivery of ssODN 24 hours later. Figure 2B Raw HA+CD5+ levels are shown, with background levels indicated as untreated (UT), covering multiple time points (D1, D2, D3) and conditions: simultaneous delivery of all components (DX all), and staggered delivery with ssODN added 24 hours after Cas9 / sgRNA treatment (DxCas9 + 24h ssODN). Each treatment was further subdivided by the weight of Cas9 mRNA / sgRNA and ssODN added per million T cells (5 μg:1 μg, 1 μg:1 μg, 5 μg:5 μg, 5 μg:10 μg). Optimal HDR efficiency was observed at the maximum test dose (5 μg Cas9 / sgRNA:10 μg ssODN per million T cells) with simultaneous delivery on all days from day 1 to day 3 (DX all), where efficiency decreased with delayed ssODN addition. Error bars represent the standard deviation between technique replicates.
[0245] Example 3
[0246] Figures 3A-3C A comparison of HDR efficiency and cell viability between different LNP configurations is shown. Figure 3A Encapsulation strategies are shown, such as encapsulating Cas9 mRNA and sgRNA in one LNP and encapsulating DNA in another LNP (“separate” encapsulation), or encapsulating all three components in the same LNP (“integrated”). Figure 3B The HDR efficiency, expressed as a percentage of HA+ CD5+ primary T cells, is shown after treatment with LNPs encapsulating CRISPR / Cas9 components either separately (Cas9 mRNA and sgRNA encapsulated in one LNP, and ssODN encapsulated in another LNP) or as a combined LNP (“integrated”). Significance of selected groups was assessed using the Student’s t-test, with ns (not significant) defined as p > 0.05. Error bars represent technical replicates of n = 3 or n = 6. Knock-in percentages are normalized relative to untreated controls. In these examples, 1 μM of HDR enhancer V2 was added to the cell culture. Figure 3C Cell viability is shown after LNP treatment with the corresponding LNP configuration (relative to the untreated control).
[0247] In this non-limiting example, a comparative study was conducted to evaluate HDR efficiency in primary T cells when delivering Cas9 mRNA, sgRNA, and ssODN using two different encapsulation strategies. Individual LNPs were used for RNA and DNA components, or all components were co-encapsulated in a single PNI 550-LNP_1 LNP formulation (see [link to PNI 550-LNP_1 LNP formulation]). Figure 3A The results, normalized relative to the unprocessed control, indicate no significant difference in HDR efficiency between the two encapsulation methods. Figure 3B By maintaining equivalent nucleic acid doses in both delivery strategies, whether using an integrated LNP formulation or LNPs alone, the percentage of HA+ / CD5+ cells was comparable. Cell viability remained consistent between the two strategies and had no effect on cell viability compared to the untreated control. Figure 3C These findings suggest that physically co-packaging RNA and DNA components into a single nanoparticle is not critical to HDR results, thus providing flexibility for the design and application of LNPs in primary T cell gene editing.
[0248] Example 4
[0249] Figures 4A-4F show the evaluation of HDR efficiency and cell viability using different concentrations of Alt-R HDR enhancer V2. Figures 4A-4C show LNPs generated on the NanoAssmblr Spark platform without further purification. Figures 4D-4F show LNPs generated on the NanoAssmblr Ignite platform after complete buffer replacement and cleaning. Figure 4A shows the HDR efficiency of PNI 550-LNP_1 LNPs containing Cas9 mRNA, sgRNA, and ssODN at different concentrations of HDR enhancer V2 as indicated by the x-axis. Figure 4B shows the corresponding normalized cell viability relative to the untreated control at the indicated HDR enhancer concentration. Figure 4C shows representative 2D flow cytometry plots showing the frequencies of HA+CD5+ T cells at 0 μM and 4 μM HDR enhancer V2, respectively. Figure 4D shows the HDR efficiency of PNI 550-LNP_1 LNPs containing Cas9 mRNA, sgRNA, and ssODN generated on the Ignite platform at different concentrations of HDR enhancer V2 as indicated. Figure 4E shows the corresponding normalized cell viability relative to the untreated control at the indicated HDR enhancer concentrations. Figure 4F shows representative 2D flow cytometry plots illustrating HA+ / CD5+ T cell frequencies at 0 μM and 4 μM HDR enhancer V2. Error bars indicate technique reproducibility.
[0250] A dose-response analysis was performed on the Alt-R HDR enhancer V2 from IDT to assess its impact on HDR efficiency. For PNI 550-LNP_1 LNPs generated by Spark, the addition of HDR enhancer V2 significantly improved HDR efficiency in a dose-dependent manner without additional LNP cleanup and downstream processing, with the highest HDR efficiency observed at an enhancer concentration of 4 μM. In contrast, LNPs generated on the Ignite platform, which includes a cleanup step, showed a slight improvement at enhancer concentrations above 1–2 μM. Importantly, both platforms allowed for significant HDR efficiencies without the addition of enhancers, reaching 26% and 41% with Spark and Ignite, respectively. However, the significantly higher editing results obtained using Ignite highlight the importance of LNP purification combined with HDR enhancers for optimizing gene editing efficiency. HDR enhancer V2 alleviated the limitations associated with unpurified LNPs, although its efficacy in purified LNPs was not significant.
[0251] Example 5
[0252] Figures 5A-5BThe effects of small molecules and nucleic acid regulators on the HDR efficiency and cell viability of PNI 550-LNP_1 LNPs were shown. Figure 5A The knock-in efficacy (KI%) of PNI 550-LNP_1 LNP at different modulator doses (0–20 μM) is shown, expressed as relative to untreated control normalized HA+ / CD5+ cells. The modulators tested included RU521 alone, Alt-R HDR enhancer V2 alone, a combination of RU521 and V2, BX795, XL413, and A151. Figure 5B The corresponding cell viability, determined by live / dead flow cytometry staining, is shown after treatment with the indicated modulator.
[0253] This study evaluated the effects of small molecule regulators and DNA oligonucleotides (A151) on HDR efficiency and cell viability. Molecules included the non-homologous end joining (NHEJ) Alt-R HDR enhancer V2, the cGAS DNA sensor inhibitor RU521, the cGAS competitive inhibitor A151, the TANK-binding kinase inhibitor BX795, and the ATP competitive inhibitor XL413. PNI 550 LNP_1 LNPs for HA-labeled CD5 were used as a model for HDR in primary T cells. BX795 was observed to enhance knock-in efficiency in a dose-dependent manner without impairing cell viability. Its mechanism of action is speculated to involve inhibition of the DNA sensor, which is advantageous for HDR applications. While HDR enhancer V2 significantly increased HDR editing rates, it significantly reduced cell viability, especially at concentrations above 10 μM, which may be related to its role as an NHEJ inhibitor. RU521, XL413, and A151 showed negligible effects on HDR, while the combination of RU521 and V2 indicated a slight enhancement. Figure 5A and 5B Among the modifiers tested, BX795 was the most effective modifier for HDR applications in terms of efficacy and potency.
[0254] Example 6
[0255] Figures 6A-6B Proprietary PNI ionizable lipids are shown compared to benchmark lipids. Figure 6A HDR knock-in efficiency is shown as a percentage relative to untreated (UT) wild-type normalized HA+ / CD5+ T cells. The ionizable lipid PNI 550 in LNP_1 exhibited high HDR efficiency (9.5%), significantly exceeding the HDR efficiency of SM-102 in Moderna's Spikevax® composition, or various benchmark lipids in the LNP_1 composition. Error bars represent the standard deviation of n = 4 technical replicates. Figure 6BThe values are shown as a percentage of HDR knock-in efficiency relative to untreated (UT) wild-type normalized GFP+ / TCR- T cells. PNI ionizable lipids in LNP_1 show a higher GFP insertion rate than MC3 in the Onpattro® composition and SM-102 in the Spikevax® composition. Error bars represent deviations between technical and biological (primary T cell donor) replicates.
[0256] Table 6 of Example 6: Lipid compositions with mol% ratios for encapsulating Cas9 mRNA, sgRNA, and ssODN in a single LNP.
[0257] exist Figures 6A-6B In the LNP_1 compositions shown, the ionizable lipids were varied by using PNI 550, PNI 580, PNI 728, PNI 768, BOCHD-C3-DMA, SM-102, or MC3 while maintaining the same molar ratio. Benchmark LNP samples containing SM-102 in Spikevax® lipid compositions or MC3 in Onpattro lipid compositions were also prepared.
[0258] Table 6
[0259]
[0260] To evaluate the potency of PNI-ionizable lipids, a non-restrictive analysis of examples of ionizable lipids was performed against known literature benchmarks, targeting LNP-mediated HDR efficiency in primary T cells. Figure 6A In this study, the ionizable lipid PNI 550 was used as a proprietary PNI lipid in a composition referred to as LNP_1. Additionally, comparative ionizable lipids included BOCHD-C3-DMA, MC3, and SM-102, all of which were tested in the same LNP_1 composition. Furthermore, SM-102 was evaluated as a component of Moderna's Spikevax composition (see Table 6, "Spikevax (SM-102)"). Figure 6A Knock-in (KI) efficiency is shown as a percentage of normalized HA+CD5+ cells relative to untreated (UT) controls. The proprietary PNI 550 lipid outperformed conventional lipids with a 9.5% knock-in efficiency, while BOCHD-C3-DMA and SM-102 in both cases (in LNP_1 or Spikevax compositions) showed significantly lower efficiencies. MC3 exhibited the lowest efficiency, indicating poor compatibility with LNP-mediated delivery of HDR components in primary T cells. Figure 6B The use of PNI lipids for HDR insertion was further elaborated by inserting a larger GFP (approximately 2.5 kb) target. Figure 6B As shown, PNI lipids performed significantly better than SM-102 (in the Spikevax composition) and MC3 (in the Onpattro composition). Testing was conducted in three replicates of healthy primary T cells, except for PNI 728, which was performed only in two of the three replicates of healthy primary T cells.
[0261] Example 7
[0262] Figures 7A-7C illustrate the HDR efficiency of different ionizable lipids in primary T cells. Figure 7A shows the HA+ / CD5+ HDR ratio percentage when using two LNP formulations (LNP_1 vs. LNP_2) and multiple ionizable lipids (PNI-550, 659, 762, 768, or 769). Figure 7B shows the corresponding 2D flow cytometry plot depicting the expression of the HA tag relative to CD5 on T cells treated with LNPs including ionizable lipids (PNI 550, PNI 762, and PNI 659) from the LNP_1 composition. Figure 7C shows the HA+ / CD5+ HDR ratio percentage when using two LNP formulations (LNP_1 vs. LNP_2) and multiple ionizable lipids (PNI-550, 762, or 516) without the addition of enhancers. Error bars indicate the standard deviation of >3 technical replicates. Figure 7D shows the CAR+ / TRAC-HDR ratio percentage for pDNA-mediated (approximately 3.5 kb) chimeric antigen receptor (CAR) targeting the TRAC locus using two LNP formulations (LNP_1 vs. LNP_2) and ionizable lipids (PNI-550, 762, or 516) at different nucleic acid (NA) doses without the addition of enhancers. Error bars indicate the standard deviation of two technical replicates.
[0263] To further develop lipid compositions for HDR, a range of proprietary PNI ionizable lipids were evaluated in both the LNP_1 and LNP_2 compositions. CD5 HA knock-in assays were performed on the ionizable lipids PNI 550, PNI 516, PNI 659, PNI 762, PNI 768, and PNI 769 in multiple experiments and with various loadings. Both LNP_1 and LNP_2 performed well with all lipids, achieving meaningful small gene insertion HDR in primary T cells (Figures 7A-7D). All LNPs generated using the ionizable lipids PNI 550, PNI 659, PNI 762, PNI 768, and PNI 769 as part of the LNP_1 composition were tested in two primary T cell donors. In both donors, all ionizable lipids showed significant HA insertion HDR efficiency, demonstrating similar performance (data not shown). Example flow cytometry illustrations of PNI 550, PNI 762, and PNI 659 are shown in Figure 7B. When the LNP compositions were changed, as shown in Figure 7C, both LNP_1 and LNP_2 performed well with PNI lipids (e.g., PNI516, 550, and 762), with all compositions achieving meaningful small gene insertion HDR in primary T cells. Finally, similar to Figure 7C, lipid nanoparticles containing LNP_1 and LNP_2, as well as PNI 550, PNI 762, and PNI 516, were tested for pDNA-mediated (approximately 3.5 kb) HDR targeting the chimeric antigen receptor (CAR) locus of the TRAC gene. As shown in Figure 7D, both LNP_1 and LNP_2 achieved comparable HDR rates, and all PNI lipids showed meaningful CAR expression. Overall, these findings suggest that ionizable PNI lipids facilitate efficient delivery of gene editing complexes and DNA, thereby improving HDR results. This enhancement can be attributed to factors such as increased release of encapsulated genetic material into the cytoplasm, improved LNP stability (e.g. in cell culture medium), and / or enhanced cellular uptake of LNPs.
[0264] Table 7 of Example 7: mol% ratio of lipid compositions used to encapsulate Cas9 mRNA, sgRNA, and DNA (ssODN or pDNA) in a single LNP. In the LNP_1 or LNP_2 compositions shown in Figures 7A-7C, the ionizable lipids were varied by using PNI 550, PNI 516, PNI 659, PNI 728, PNI 762, PNI 768, or PNI 769 while maintaining the same molar ratio.
[0265] Table 7.
[0266]
[0267] Example 8
[0268] Figures 8A-8B The HDR efficiency of various LNP formulations in primary T cells with and without Alt-R HDR enhancer V2 is shown. Figure 8A An evaluation of HDR efficiency using LNP formulated with PNI 550 ionizable lipids is shown, with and without the indicated HDR enhancer. Figure 8B Parallel evaluations of compositions employing PNI 762 ionizable lipids are shown. Error bars indicate two technical replicates.
[0269] The LNP compositions were further improved based on the parameters for establishing cell density, processing kinetics, delivery, encapsulation strategies, and ionizable lipid efficacy outlined in Examples 1-7.
[0270] The analysis focused on a range of LNP compositions, each designed to test the synergistic effect between ionizable lipids and auxiliary lipid components. The compositions are shown below, with composition ratios expressed as molar percentages.
[0271] Table 8 of Example 8: mol% ratio of lipid compositions used to encapsulate Cas9 mRNA, sgRNA and ssODN in a single LNP.
[0272] Table 8
[0273]
[0274]
[0275] exist Figure 8A and 8B In this study, PNI 550 and PNI 762 lipids were used as ionizable lipids in various compositions, according to their corresponding descriptions specified in Table 8. Among the samples tested, LNP_1 achieved the highest HDR efficiency. Other compositions (e.g., Figure 8A LNP3 in, and Figure 8B The LNP_2 and DDM in the model also achieved significant HDR efficiency.
[0276] Example 9
[0277] To further optimize the LNP_1 LNP composition for HDR in primary T cells, a design-of-experiment (DoE) approach was used to investigate the interactions between PNI 550 and other lipid components that may further enhance gene editing efficiency.
[0278] The following composition was tested in primary T cells.
[0279] Table 9 of Example 9: mol% ratio of lipid compositions used to encapsulate Cas9 mRNA, sgRNA, and ssODN in a single LNP. LNP_1 was tested as PNI 550-LNP_1 and PNI 762-LNP_1.
[0280] Table 9
[0281]
[0282] Figures 9A-9B The HDR efficiency and cell viability of different LNP formulations are shown. Figure 9A The HDR efficiency, expressed as the percentage of HA+ / CD5+ primary T cells, is shown after treatment with various LNP formulations, including PNI 550-LNP_1 and the previously identified PNI 762-LNP_1. Formulation PNI 762-LNP_1 exhibited the highest HDR efficiency among the compositions tested. Figure 9B The corresponding cell viability, determined by flow cytometry, is shown. Viability is normalized relative to untreated wild-type controls. Error bars indicate technique reproducibility. HDR enhancers or analogues were not included in the experiments.
[0283] like Figure 9A As shown, all formulations containing PNI-ionizable lipids were significantly superior to conventional lipid formulations. Among the test samples containing PNI-ionizable lipids, the highest HA+ / CD5+ cell populations were observed in LNP_1 (40:20:37.5:2.5 mol%), HDR_DoE1_S3 (50:10:37.5:2.5 mol%), and HDR_DoE1_S10 (40:10:48.83:1.17 mol%). The high efficacy of the high cholesterol content in the LNP formulations can be attributed to the ability of cholesterol to enhance membrane rigidity, thereby allowing for enhanced LNP stability and preventing premature release of the payload during cell delivery.
[0284] Figures 9A-9BThe baseline lipid formulations used included published optimized lipid formulations for DNA delivery to T cells, namely “7-CAR, 9-CAR, 11-CAR” (Prazeres, P. et al., Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells, International Journal of Nanomedicine, 5891-5904, 2023). The 7-CAR, 9-CAR, and 11-CAR LNPs were prepared according to specified ratios of C12-200, DOPE, cholesterol, and C14-PEG2000 (as shown in the table of Example 9). In experiments, the resulting particles showed suitable size and encapsulation efficacy for 7-CAR, 9-CAR, and 11-CAR as reported in the literature, although no significant HDR insertion was observed in primary T cells using these baseline compositions. After LNP transfection, the viability of the T cells obtained from the test samples remained at a high level. Figure 9B ).
[0285] Example 10
[0286] The PNI 550-LNP_1 LNP was benchmarked against electroporation, a commonly used T-cell gene editing technique. CD5 HA markers were used for knock-in assessment, along with cell viability measured by flow cytometry and cell counting using acridine orange / propidium iodide (AO / PI) staining. Results represent two biological replicates and three technical replicates.
[0287] Figures 10A-10C The comparison of HDR efficiency, cell viability, and yield between electroporation and PNI 550-LNP_1 LNP delivery is shown. Figure 10A The efficiency of HDR-mediated HA tag knock-in in primary T cells is shown. Both electroporation (EP) and the PNI 550-LNP_1 LNP delivery method achieved similar HDR rates, as indicated by the percentage of HA+ / CD5+ cells normalized relative to untreated controls (wt UT). Figure 10B Cell viability after treatment, as assessed by flow cytometry, is shown. The percentage of cell viability shows that PNI 550-LNP_1 LNP delivery (viability of 103% relative to the untreated control) was slightly better than electroporation (viability of 95%). Figure 10CThe edited cell yield (HA+ cell count per mL) determined by AO / PI staining and automated cell counting is shown. HA+ cell yield generated by PNI 550-LNP_1 LNP delivery (2 × 10⁻⁶ cells per mL) 5 The number of counts was significantly higher than that of electroporation (4 × 10⁻⁶ per mL). 4 (Number of counts). Error bars represent the standard deviation of the measurements, and individual data points from each biological repetition are shown as points on a bar chart. HDR enhancers were not included in the experiment.
[0288] The results showed that, in a given population, delivery of HDR nucleic acids using LNP matched electroporation in terms of HA knock-in percentage, while demonstrating comparable cell viability as confirmed by flow cytometry (with LNP showing slightly higher cell viability). However, the most significant effect between the two delivery systems was post-editing cell yield. Automated cell counting after AO / PI staining showed a substantial increase in HA+ cell yield with LNP delivery compared to electroporation, achieving a more than 5-fold improvement in cell recovery using PNI 550 LNP_1 LNP. It is speculated that electroporated cells either had a reduced proliferation rate (resulting in fewer cells in the population) or died shortly after electroporation, and debris was washed away during the culture / staining process (making the viability percentage unaffected by readings on day 4 post-treatment).
[0289] Example 11
[0290] Figure 11A-11E This study demonstrates the multi-donor performance of LNP- or electroporation (EP)-mediated HDR. PNI 762-LNP_1 containing Cas9 mRNA, TRAC7 sgRNA, and CD19 nanoparticles was added to primary T cells on day 3 post-thawing and activation. Performance metrics were evaluated on day 7 post-thawing. Figure 11A Anti-CD19-CAR+ / TCR- live cells were shown when the construct was inserted via LNP or EP. Figure 11B The corresponding cell viability, as determined by flow cytometry, is shown. Figure 11C The data shows the fold increase of gene-inserted T cells relative to the initial cell number on day 7. Figure 11D The CD19 CAR+ cell yield per 10,000 treated cells is shown, as determined by total viable cell count and gene insertion rate. Figure 11A-11D This represents the average performance across at least two technical replicates in n = 6 unique experiments covering n = 4 unique T cell donors and n = 3 unique T cell donors for EP. Figure 11EHDR CAR T cells with PNI 762-LNP_1 are shown alongside SUP-B15 cells (solid line) incubated at the specified effector-to-target ratio (48 hours). CD19-negative K562 cells (dashed line) are incubated alongside CAR T cells at an equivalent dose as a negative control. Data represent the mean of n = 2 technical replicates from n = 1 healthy T cell donor.
[0291] The delivery of a 3.5 kb anti-CD19 CAR construct for HDR in primary T cells was further compared between electroporation and LNP. The relative efficiency of the delivery methods was assessed by quantifying CD19-CAR knock-in efficiency, cell viability, cell proliferation, and CAR+ cell yield. Figure 11A-11D The experiment did not contain HDR enhancers. As shown in the provided figures, multi-donor analysis of the data indicates that LNP delivery achieved knock-in efficiency comparable to electroporation. Figure 11A Notably, significant inter-donor variability was observed in electroporation efficiency, ranging from 3% to 30%, while LNP maintained better inter-donor reproducibility. LNP showed higher cell viability on day 7 post-thawing and allowed for a 10-fold increase in T cell population proliferation. Overall, LNP-treated cells produced significantly more CD19-CAR-positive cells compared to electroporation.
[0292] The function of LNP-mediated CD19 CAR T cell clearance of CD19+ B cells (SUP-B15 cell line) was evaluated, with CD19- (K562 cell line) used as a negative control. Figure 11E As shown, the resulting LNP-engineered CAR T cells were functional and, at the lowest test effector-to-target ratio, eliminated almost all CD19+ cells within 48 hours. At lower ratios, K562 (CD19-) cells were unaffected, while at higher ratios, a small number of cells died, likely due to crowding within the assay plate.
[0293] These findings suggest that LNPs provide a superior platform for delivering large gene constructs, such as CD19 CARs, into primary T cells. High knock-in efficiency, especially when combined with high cell yield, highlights the advantages of LNPs in cell-based therapy development.
[0294] Although specific embodiments of the invention have been described and illustrated, such embodiments should be considered illustrative only and not as limiting the invention as interpreted in accordance with the appended claims.
Claims
1. A lipid nanoparticle (LNP) for transfecting hematopoietic lineage cells, said lipid nanoparticle (LNP) comprising a lipid mixture composition comprising ionizable lipids, said lipid mixture composition encapsulating HDR template DNA, said HDR template DNA comprising a gene of interest for insertion into a target chromosomal locus.
2. The lipid nanoparticles according to claim 1, wherein the HDR template DNA is double-stranded.
3. The lipid nanoparticles according to claim 1, wherein the HDR template DNA is single-stranded.
4. The lipid nanoparticles according to any one of claims 1 to 3, wherein the HDR template DNA It includes chimeric antigen receptors.
5. The lipid nanoparticles according to any one of claims 1 to 4, further comprising a nuclease or mRNA encapsulated by the lipid mixture composition, wherein the mRNA encapsulates the nuclease.
6. The lipid nanoparticles according to claim 5, wherein the endonuclease is a CRISPR-associated endonuclease.
7. The lipid nanoparticles according to any one of claims 1 to 6, further comprising guide RNA.
8. The lipid nanoparticles according to any one of claims 1 to 4, wherein the HDR template DNA is accompanied by a guide RNA in combination with a nuclease or an mRNA encoding the nuclease.
9. The lipid nanoparticles according to any one of claims 1 to 8, wherein the lipid mixture composition provides higher knock-in efficiency in primary T cells via LNP-mediated delivery of the HDR template DNA compared to lipid mixture compositions comprising MC3 (4-(dimethylamino)butyric acid, (10Z,13Z)-1-(9Z,12Z)-9,12-octadecadien-1-yl-10,13-nonadecanadien-1-yl ester) or SM-102 (8-{(2-hydroxyethyl)[6-oxo-6-(undecoxy)hexyl]amino}octanoic acid 9-heptadecyl ester).
10. The lipid nanoparticles according to any one of claims 1 to 9, wherein the ionizable lipid comprises a tetrahydrofuranyl or cyclopentyl head group.
11. The lipid nanoparticles according to any one of claims 1 to 10, wherein the ionizable lipid comprises PNI516, PNI 550, PNI 580, PNI 659, PNI 714, PNI 726, PNI 728, PNI 761, PNI 762, PNI 768, PNI 769, PNI 771, or any combination thereof.
12. The lipid nanoparticles according to any one of claims 1 to 11, wherein the lipid mixture composition further comprises structural lipids, sterols, stabilizers, or any combination thereof.
13. The lipid nanoparticles according to any one of claims 1 to 12, wherein the stabilizer comprises polyoxyethylene (10) stearyl ether (BrijS10), tocopherol polyethylene glycol succinate (TPGS), PEG-DMG, dodecyl maltodextrin, sucrose monolaurate, or any combination thereof.
14. The lipid nanoparticles according to claim 12 or 13, wherein the lipid mixture composition comprises about 20-50 mol% ionizable lipids, about 10-70 mol% structured lipids, about 10-70 mol% sterols and about 0.5-3 mol% stabilizers, wherein the total mol% of the components in the lipid mixture composition is 100 mol%.
15. The lipid nanoparticles according to any one of claims 12 to 14, wherein the lipid mixture composition comprises about 40 Mol% ionizable lipids, about 20 Mol% distearate phosphatidylcholine (DSPC), about 37.5 Mol% cholesterol and about 2.5 Mol% polyoxyethylene (10) stearyl ether (BrijS10).
16. The lipid nanoparticles according to any one of claims 12 to 14, wherein the lipid mixture composition comprises about 40 mol% ionizable lipids, about 20 mol% distearate phosphatidylcholine (DSPC), about 39 mol% cholesterol, and about 0.75 mol% tocopherol polyethylene glycol 1000 succinate (TPGS).
17. A lipid mixture composition for encapsulating HDR template DNA, the HDR template DNA comprising a gene of interest for insertion into a desired chromosomal locus, the lipid mixture composition comprising ionizable lipids.
18. The lipid mixture composition of claim 17, wherein the lipid mixture composition provides higher knock-in efficiency in primary T cells via LNP-mediated delivery of the HDR template DNA compared to lipid mixture compositions comprising MC3 (4-(dimethylamino)butyric acid, (10Z,13Z)-1-(9Z,12Z)-9,12-octadecadien-1-yl-10,13-nonadecanadien-1-yl ester) or SM-102 (8-{(2-hydroxyethyl)[6-oxo-6-(undecanoxy)hexyl]amino}octanoic acid 9-heptadecyl ester).
19. The lipid mixture composition according to claim 17 or 18, wherein the ionizable lipid comprises a tetrahydrofuranyl or cyclopentyl head group.
20. The lipid mixture composition according to any one of claims 17 to 19, wherein the ionizable lipid comprises PNI 516, PNI 550, PNI 580, PNI 659, PNI 714, PNI 726, PNI 728, PNI 761, PNI 762, PNI 768, PNI 769, PNI 771, or any combination thereof.
21. The lipid mixture composition according to any one of claims 17 to 20, wherein the lipid mixture composition further comprises a structural lipid, a sterol, a stabilizer, or any combination thereof.
22. The lipid mixture composition of claim 21, wherein the stabilizer comprises polyoxyethylene (10) stearyl ether (BrijS10), tocopherol polyethylene glycol succinate (TPGS), PEG-DMG, dodecyl maltodextrin, sucrose monolaurate, or any combination thereof.
23. The lipid mixture composition according to claim 21 or 22, comprising about 20-50 mol% ionizable lipids, about 10-70 mol% structured lipids, about 10-70 mol% sterols and about 0.5-3 mol% stabilizers, wherein the total mol% of the components in the lipid mixture composition is 100 mol%.
24. The lipid mixture composition according to any one of claims 21 to 23, wherein the lipid mixture composition comprises about 40 mol% ionizable lipids, about 20 mol% distearate phosphatidylcholine (DSPC), about 37.5 mol% cholesterol and about 2.5 mol% polyoxyethylene (10) stearyl ether (BrijS10).
25. The lipid mixture composition according to any one of claims 21 to 23, wherein the lipid mixture composition comprises about 40 mol% ionizable lipids, about 20 mol% distearate phosphatidylcholine (DSPC), about 39 mol% cholesterol, and about 0.75 mol% tocopherol polyethylene glycol 1000 succinate (TPGS).
26. A method for transfecting hematopoietic lineage cells, the method comprising: Hematopoietic lineage cells are contacted with lipid nanoparticles (LNPs) comprising a lipid mixture composition containing ionizable lipids, the lipid mixture composition encapsulating HDR template DNA containing a gene of interest for insertion into a desired chromosomal locus, thereby transfecting the cells; and The cells are cultured in a cell culture medium.
27. The method of claim 26, further comprising isolating the cells from the cell culture medium.
28. The method of claim 26 or 27, wherein the HDR template DNA is double-stranded.
29. The method of claim 26 or 27, wherein the HDR template DNA is single-stranded.
30. The method according to any one of claims 26 to 29, wherein the HDR template DNA comprises a chimeric antigen receptor.
31. The method according to any one of claims 26 to 30, wherein the HDR template DNA is accompanied by a nuclease or mRNA encoding the nuclease.
32. The method according to claim 31, wherein the endonuclease is a CRISPR-associated endonuclease.
33. The method according to any one of claims 26 to 32, wherein the HDR template DNA is accompanied by a single-guide RNA.
34. The method according to any one of claims 26 to 30, wherein the cell is contacted with the LNP containing the HDR template DNA, the HDR template DNA being accompanied by a guide RNA combined with a nuclease or an mRNA encoding the nuclease.
35. The method according to any one of claims 26 to 30, wherein the cell is contacted with a plurality of LNPs, each of the plurality of LNPs comprising the HDR template DNA, guide RNA and / or endonuclease.
36. The method according to any one of claims 26 to 35, further comprising contacting the cell with a homology-directed repair enhancer, wherein the homology-directed repair enhancer comprises an HDR enhancer, an NHEJ inhibitor, a DNA sensor inhibitor, or a cell cycle synchronization molecule.
37. The method according to any one of claims 26 to 36, wherein the target cell density is between 100,000 cells / mL and 1,000,000 cells / mL.
38. The method according to any one of claims 26 to 37, wherein contacting hematopoietic lineage cells comprises transfecting primary T cells with the lipid nanoparticles (LNPs), wherein the LNPs, when delivering the HDR template DNA in primary T cells, provide higher knock-in efficiency compared to lipid nanoparticles comprising MC3 (4-(dimethylamino)-butyric acid, (10Z,13Z)-1-(9Z,12Z)-9,12-octadecadien-1-yl-10,13-nonadecanadien-1-yl ester) or SM-102 (8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoic acid 9-heptadecyl ester).
39. The method according to any one of claims 26 to 38, wherein the ionizable lipid comprises a tetrahydrofuranyl or cyclopentyl head group.
40. The method according to any one of claims 26 to 39, wherein the ionizable lipid comprises PNI 516, PNI 550, PNI 580, PNI 659, PNI 714, PNI 726, PNI 728, PNI 761, PNI 762, PNI 768, PNI 769, PNI 771, or any combination thereof.
41. The method according to any one of claims 26 to 40, wherein the lipid mixture composition of said LNP further comprises structural lipids, sterols, stabilizers, or any combination thereof.
42. The method of claim 41, wherein the stabilizer comprises polyoxyethylene (10) stearyl ether (BrijS10), tocopherol polyethylene glycol succinate (TPGS), PEG-DMG, dodecyl maltodextrin, sucrose monolaurate, or any combination thereof.
43. The method according to claim 41 or 42, wherein the lipid mixture composition comprises about 20-50 mol% ionizable lipids, about 10-70 mol% structured lipids, about 10-70 mol% sterols and about 0.5-3 mol% stabilizers, wherein the total mol% of the components in the lipid mixture composition is 100 mol%.
44. The method according to any one of claims 41 to 43, wherein the lipid mixture composition comprises about 40 mol% ionizable lipids, about 20 mol% distearate phosphatidylcholine (DSPC), about 37.5 mol% cholesterol and about 2.5 mol% polyoxyethylene (10) stearyl ether (BrijS10).
45. The method according to any one of claims 41 to 43, wherein the lipid mixture composition comprises about 40 mol% ionizable lipids, about 20 mol% distearate phosphatidylcholine (DSPC), about 39 mol% cholesterol, and about 0.75 mol% tocopherol polyethylene glycol 1000 succinate (TPGS).
Citation Information
Patent Citations
Bifurcating mixers and methods of their use and manufacture
US10076730B2
Device for formulating particles at small volumes
US10159652B2
Laminar mixing apparatus and methods
US20040262223A1
Sample Processing System and Methods
US20110003380A1
Compositions for the introduction of polyanionic materials into cells
US5753613A
